United States Securities and Exchange Commission
Washington, D.C. 20549
FORM 10-Q
(Mark One)
[X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended September 30, 2004
---------------------------
OR
[ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
For the transition period from ____________ to _____________
Commission file number 0-27354
Impax Laboratories, Inc.
------------------------------------------------------
(Exact name of registrant as specified in its charter)
Delaware 65-0403311
------------------------------- -------------------
(State or other jurisdiction of (I.R.S. Employer
incorporation or organization) Identification No.)
30831 Huntwood Avenue - Hayward, California 94544
-----------------------------------------------------------
(Address of principal executive offices) (Zip code)
Registrant's telephone number including area code (510) 476-2000
---------------------
Indicate by check mark whether the registrant (1) has filed all reports required
to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during
the preceding 12 months (or for such shorter period that the registrant was
required to file such reports) and (2) has been subject to such filing
requirements for the past 90 days. Yes __X__ No _____
Indicate by check mark whether registrant is an accelerated filer (as defined in
Rule 12b-2 of the Act.) Yes __X__ No ____
The number of shares outstanding of the registrant's common stock as of
October 31, 2004 was approximately 58,484,718.
---------------- -----------
IMPAX LABORATORIES, INC.
INDEX TO FORM 10-Q
FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2004
PART I. FINANCIAL INFORMATION
PAGE
----
Item 1. Financial Statements:
Condensed Balance Sheets as of September 30, 2004 and December 31, 2003 (unaudited) ...................... 1
Condensed Statements of Income for the Three Months and Nine Months
Ended September 30, 2004 and 2003 (unaudited) ...................................................... 2
Condensed Statements of Cash Flows for the Nine Months Ended September 30, 2004 and 2003(unaudited)....... 3
Notes to Financial Statements (unaudited) ................................................................ 4
Item 2. Management's Discussions and Analysis of Financial Condition and Results of Operations.................... 13
Item 3. Quantitative and Qualitative Disclosures About Market Risk................................................ 26
Item 4. Controls and Procedures................................................................................... 26
PART II. OTHER INFORMATION AND SIGNATURES
Item 1. Legal Proceedings......................................................................................... 27
Item 6. Exhibits.................................................................................................. 32
Signatures .................................................................................................... 34
Certifications .................................................................................................... 35
i
PART I - FINANCIAL INFORMATION
------------------------------
ITEM 1. FINANCIAL STATEMENTS
IMPAX LABORATORIES, INC.
CONDENSED BALANCE SHEETS
(UNAUDITED)
(IN THOUSANDS, EXCEPT SHARE AND PER SHARE DATA)
SEPTEMBER 30, DECEMBER 31,
2004 2003
-------- ---------
ASSETS
Current assets:
Cash and cash equivalents $ 44,782 $ 15,505
Short term investments 44,821 --
Accounts receivable, net 19,730 9,885
Inventory 38,232 28,479
Prepaid expenses and other assets 2,735 1,427
-------- ---------
Total current assets 150,300 55,296
Restricted cash - 10,000
Property, plant and equipment, net 43,849 38,132
Investments and other assets 3,673 1,325
Goodwill, net 27,574 27,574
Intangibles, net 91 379
-------- ---------
Total assets $225,487 $ 132,706
======== =========
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Current portion of long-term debt $ 912 $ 1,068
Accounts payable 12,641 22,783
Revolving line of credit 5,000 7,642
Accrued expenses and deferred revenues 15,336 10,872
-------- ---------
Total current liabilities 33,889 42,365
Convertible senior subordinated debentures 95,000 --
Refundable deposit from Teva -- 5,000
Long term debt 7,284 8,854
Deferred revenues and other liabilities 2,978 2,879
-------- ---------
Total liabilities 139,151 59,098
-------- ---------
Commitments and Contingencies
Mandatorily redeemable convertible Preferred Stock: Series 2 mandatory
redeemable convertible Preferred Stock, $0.01 par value 0 shares
outstanding at September 30, 2004, and 75,000 shares outstanding at
December 31, 2003,
redeemable at $100 per share 0 7,500
-------- ---------
Stockholders' equity:
Common stock, $0.01 par value, 90,000,000 shares authorized and
58,478,671 and 55,307,136 shares issued and outstanding
at September 30, 2004, and December 31, 2003, respectively 585 553
Additional paid-in capital 184,028 170,104
Accumulated deficit (98,277) (104,549)
-------- ---------
Total stockholders' equity 86,336 66,108
-------- ---------
Total liabilities and stockholders' equity $225,487 $ 132,706
======== =========
The accompanying notes are an integral part of these financial statements.
1
IMPAX LABORATORIES, INC.
CONDENSED STATEMENTS OF INCOME
(UNAUDITED)
(DOLLARS IN THOUSANDS, EXCEPT SHARE AND PER SHARE DATA)
Three Months Ended Nine Months Ended
September 30, September 30,
------------------------------ -------------------------------
2004 2003 2004 2003
----------- ----------- ----------- -----------
Net sales $ 30,261 $ 15,908 $ 91,798 $ 40,434
Revenue from reversal of
refundable deposit from Teva -- -- 2,500 --
Other revenues 443 589 1,515 1,555
----------- ----------- ----------- -----------
Total revenues 30,704 16,497 95,813 41,989
----------- ----------- ----------- -----------
Cost of sales 17,592 12,976 54,679 30,444
----------- ----------- ----------- -----------
Gross margin 13,112 3,521 41,134 11,545
Research and development 4,942 3,358 15,266 10,463
Reimbursements from Teva (217) (93) (306) (247)
----------- ----------- ----------- -----------
Research and development, net 4,725 3,265 14,960 10,216
Patent litigation expenses 3,299 845 7,146 1,842
Selling expenses 908 546 2,345 1,552
General and administrative expenses 3,289 2,321 9,757 6,526
Other operating income (expense), net 4 4 15 25
----------- ----------- ----------- -----------
Net income (loss) from operations 895 (3,452) 6,941 (8,566)
Interest income 387 87 714 199
Interest expense (547) (243) (1,383) (738)
----------- ----------- ----------- -----------
Net income (loss) before provision for income taxes $ 735 $ (3,608) $ 6,272 $ (9,105)
----------- ----------- ----------- -----------
Provision for income taxes -- -- -- --
----------- ----------- ----------- -----------
Net income (loss) $ 735 $ (3,608) $ 6,272 $ (9,105)
=========== =========== =========== ===========
Earnings (loss) per share:
Basic $ 0.01 $ (0.07) $ 0.11 $ (0.18)
----------- ----------- ----------- -----------
Diluted $ 0.01 $ (0.07) $ 0.10 $ (0.18)
----------- ----------- ----------- -----------
Weighted average common shares outstanding:
Basic 58,469,272 52,610,356 57,855,637 50,382,455
=========== =========== =========== ===========
Diluted 62,137,376 52,610,356 61,352,899 50,382,455
=========== =========== =========== ===========
The accompanying notes are an integral part of these financial statements.
2
IMPAX LABORATORIES, INC.
CONDENSED STATEMENTS OF CASH FLOWS
(UNAUDITED)
(DOLLARS IN THOUSANDS)
NINE MONTHS ENDED
SEPTEMBER 30,
---------------------------
2004 2003
-------- --------
CASH FLOWS FROM OPERATING ACTIVITIES:
Net income (loss) $ 6,272 $ (9,105)
Adjustments to reconcile net income (loss) to net cash used by operating activities:
Depreciation and amortization 3,263 2,718
Reversal of refundable deposit from Teva (2,500) --
Non-cash compensation charge (options) 87 437
Change in assets and liabilities:
Accounts receivable (9,845) (1,375)
Inventory (9,753) (9,385)
Prepaid expenses and other assets (45) (287)
Accounts payable (10,142) 8,035
Other liabilities 4,562 (861)
-------- --------
Net cash (used in) operating activities (18,101) (9,823)
-------- --------
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of short term investments (44,821) --
Purchases of property and equipment (8,692) (3,063)
-------- --------
Net cash (used in) by investing activities (53,513) (3,063)
-------- --------
CASH FLOWS FROM FINANCING ACTIVITIES:
Revolving line of credit borrowings (repayments) (2,710) 1,196
Additions to long-term debt -- 896
Repayment of long-term debt (1,656) (674)
Proceeds from convertible debentures 95,000 --
Capitalized Financing Costs (3,612) --
Reversal of Restricted Cash 10,000 --
Net proceeds from sale of common stock -- 23,298
Proceeds from issuance of common stock (upon exercise of
stock options and warrants) 3,869 433
-------- --------
Net cash provided by financing activities 100,891 25,149
-------- --------
Net increase in cash and cash equivalents 29,277 12,263
-------- --------
Cash and cash equivalents, beginning of the period $ 15,505 $ 10,219
-------- --------
Cash and cash equivalents, end of the quarter $ 44,782 $ 22,482
======== ========
Cash paid for interest $ 1,383 $ 447
======== ========
Cash paid for income taxes $ -- $ --
======== ========
The accompanying notes are an integral part of these financial statements.
3
NOTES TO CONDENSED FINANCIAL STATEMENTS
NINE MONTHS ENDED
SEPTEMBER 30, 2004 AND SEPTEMBER 30, 2003
(UNAUDITED)
NOTE 1. These condensed financial statements included herein have been prepared
by the Company pursuant to the rules and regulations of the Securities and
Exchange Commission. Certain information and disclosures normally included in
financial statements prepared in accordance with accounting principles generally
accepted in the United States of America have been condensed or omitted pursuant
to such rules and regulations; however, the Company believes that the
disclosures are adequate to make the information presented not misleading. These
financial statements should be read in conjunction with the financial statements
and the notes thereto included in the Company's latest Annual Report on Form
10-K. The results of operations for the three and nine months ended September
30, 2004 are not necessarily indicative of the results of operations expected
for the year ending December 31, 2004.
Impax Laboratories, Inc. ("IMPAX," "we," "us," or "the Company") focuses on the
development, manufacturing, and marketing of specialty pharmaceutical products
utilizing formulation expertise and drug delivery technologies. As of September
30, 2004, the Company marketed thirty-three generic pharmaceuticals, which
represent dosage variations of fourteen different pharmaceutical compounds, and
has fourteen applications under review with the Food and Drug Administration
(FDA), including four tentatively approved. Nine of these pending filings were
filed under Paragraph IV of the Hatch-Waxman Amendments. The Company has
approximately twenty-five other products in various stages of development for
which applications have not yet been filed.
The Drug Price Competition and Patent Term Restoration Act of 1984, referred to
as the Hatch-Waxman Amendments, established an abbreviated new drug application
("ANDA") procedure for obtaining FDA approval of generic versions of certain
drugs. An ANDA is similar to a new drug application ("NDA") except that the FDA
waives the requirement that the applicant conduct and submit to the FDA clinical
studies to demonstrate the safety and effectiveness of the drug. Instead, for
drugs that contain the same active ingredient and are of the same route of
administration, dosage form, strength and indication(s) as drugs already
approved for use in the United States, the FDA ordinarily only requires
bioavailability data demonstrating that the generic formulation is bioequivalent
to the previously approved reference listed drug, and indicating that the rate
of absorption and the levels of concentration of the generic drug in the body do
not show a significant difference from those of the previously approved
reference listed drug product. According to information published by the FDA,
the FDA currently takes approximately 18 to 20 months on average to approve an
ANDA following the date of its first submission to the FDA.
Patent certification requirements for generic drugs could also result in
significant delays in obtaining FDA approvals. First, where patents covering a
reference listed drug are alleged to be invalid, unenforceable, or not infringed
by an ANDA applicant, the holder or holders of the brand name drug patents may
institute patent infringement litigation and obtain a stay of up to 30 months
after approval of an ANDA, and for ANDAs of products whose patent information
was listed before August 2003, potentially multiple 30 month stays. Second, the
first company to submit an ANDA for a given drug, which the FDA accepts for
filing, and which certifies that an unexpired patent covering the reference
listed brand name drug is invalid, unenforceable, or will not be infringed by
its product, can be awarded 180 days of market exclusivity following approval of
its ANDA, during which the FDA may not approve any other ANDAs for that drug
product.
Except for the nine months ended September 30, 2004 we have experienced
operating losses in each quarter since our inception and our future
profitability continues to be uncertain. We have also experienced negative cash
flow from operations. As of September 30, 2004, our accumulated deficit was
$98,277,000 and we had outstanding indebtedness in an aggregate principal amount
of $108,196,000. To remain operational, we must, among other things:
o obtain FDA approvals for our products;
o prevail in the patent infringement litigation in which we are involved;
o successfully launch our new products; and
o comply with the many complex governmental regulations that deal with
virtually every aspect of our business activities.
We expect to incur significant operating expenses, particularly research and
development and patent litigation, for the foreseeable future in order to
execute our business plan. We, therefore, anticipate that such operating
expenses, as well as planned capital expenditures for the next twelve months
ranging from $15 to $20 million, primarily in plant capacity expansion, will
constitute a material use of our cash resources.
To date, the Company has primarily funded its research and development and other
operating activities through equity, debt financings and strategic alliances.
4
CRITICAL ACCOUNTING POLICY RELATED TO REVENUE RECOGNITION
The Company recognizes revenue in accordance with SEC Staff Accounting Bulletin
("SAB") 101 issued by the SEC in December 1999. We recognize revenue from the
sale of products when the shipment of products is received and accepted by the
customer. Provisions for estimated discounts, rebates, chargebacks, returns and
other adjustments are provided for in the period the related sales are recorded.
In December 2003, SAB 104 was issued by the SEC. This bulletin clarifies
portions of Topic 13 of the Staff Accounting Bulletin to be consistent with
current accounting and auditing guidance and SEC rules and regulations. This
bulletin also revises the accounting guidance contained in SAB 101 related to
multiple element revenue arrangements of Emerging Issues Task Force (EITF) No.
00-21.
EITF No. 00-21 supplemented SAB 101 for accounting for multiple element
arrangements. The Company has entered into several strategic alliances that
involve the delivery of multiple products and services over an extended period
of time. In multiple element arrangements, the Company must determine whether
any or all of the elements of the arrangement can be separated from one another.
If separation is possible, revenue is recognized for each deliverable when the
revenue recognition criteria for the specific deliverable is achieved. If
separation is not possible, revenue recognition is required to be spread over an
extended period.
Under EITF No. 00-21, in an arrangement with multiple elements, the delivered
item should be considered a separate unit of accounting if all of the following
criteria are met:
1) the delivered item has value to the customer on a standalone basis;
2) there is objective and reliable evidence of the fair value of the
undelivered item; and
3) if the arrangement included a general right of return, whether
delivery or performance of the undelivered item is considered
probable.
The Company reviews all of the terms of its strategic alliances and follows the
guidance from SAB 104 and EITF No. 00-21 for multiple element arrangements.
Upfront and milestone payments from these strategic alliances are deferred and
recognized over the life of the agreements as the Company fulfills its
contractual obligation to manufacture and supply products during this period. In
addition, in some agreements, the Company receives and records royalty revenue
based on a percentage of the strategic partner's total sales to their customers
of the products supplied by IMPAX.
In June 2001, the Company entered into a Strategic Alliance Agreement with a
subsidiary of Teva for twelve controlled-release generic pharmaceutical
products. The agreement granted Teva exclusive U.S. prescription marketing
rights for these products for a period of ten years from the date of Teva's
first sale of the products. Under the terms of this agreement, Teva has sole and
exclusive right to determine all terms and conditions of sale to its customers,
including pricing, discounts, allowances, price adjustments, returns and
rebates.
Revenues from product sales for these products under our strategic alliance are
recognized at the time title and risk of loss transfers to Teva's customers.
Because the terms are FOB destination, title and risk of loss transfer to Teva
customers upon their receipt. During the nine months ended September 30, 2004,
the Company commenced shipping its Bupropion Hydrochloride 100 mg and 150 mg
Controlled Release Tablets. The Company commenced shipping its Omeprazole 10 mg
and 20 mg delayed release products during the 2004 third quarter. Teva ships the
Bupropion and Omeprazole products to its customers and reports the results on a
monthly basis. Teva provides to IMPAX a financial report detailing its gross
sales less applicable chargebacks, rebates and other credits to arrive at net
sales, cost of sales information and gross margins for the Bupropion and
Omeprazole products. The information on the financial report is used by IMPAX to
record its monthly revenue for the Bupropion and Omeprazole products. The
Company is endeavoring to take steps under the Strategic Alliance Agreement to
ensure that all such adjustments granted by its strategic partner in the future
are reported to the Company on a timely basis. These steps include, but are not
limited to, regular discussions with Teva management regarding their monthly
financial reports to IMPAX on our products marketed by Teva via monthly
teleconferences and quarterly meetings. These discussions will cover all the
areas of revenue recognition for these products, including but not limited to,
sales credits, product returns and internal controls over Teva's financial
reporting to IMPAX. Our procedures will include a review of applicable
documentation for IMPAX revenue sharing. The Audit Committee of the Company's
Board of Directors may take additional steps as deemed necessary. Under the
contract terms, the Company has the option to perform an annual audit with our
strategic partner. We are also estimating returns for prescription products
marketed by our strategic partners, such as Teva, called "Rx Partners," based on
our internal returns analysis and historical industry statistics. The amount of
revenue that IMPAX earns is based on reimbursements of manufacturing cost plus a
fixed gross margin sharing percentage.
Under the July 2003 Exclusivity Transfer Agreement with Andrx and Teva
pertaining to the Bupropion Hydrochloride products, Andrx is entitled to certain
payments for the sales of the 150 mg strength for a six month period from the
product launch date. These payments are made directly by Teva to Andrx.
5
EARNINGS PER SHARE (EPS)
Basic earnings per share is computed by dividing net income by the weighted
average common shares outstanding. Diluted earnings per share is based on the
treasury stock method and is computed by dividing net income by the weighted
average number of common shares and dilutive potential common shares
outstanding, assuming the exercise of all in-the-money stock options. A
reconciliation of the numerators and denominators of basic and diluted earnings
per share consisted of the following (in thousands, except share and per share
amounts):
Three Months Ended Nine Months Ended
September 30, September 30,
----------------------------- -----------------------------
2004 2003 2004 2003
----------- ----------- ----------- -----------
Numerator:
Net income (loss) $ 735 $ (3,608) $ 6,272 $ (9,105)
=========== =========== =========== ===========
Denominator:
Basic weighted average common shares
outstanding 58,469,272 52,610,356 57,855,637 50,382,455
=========== =========== =========== ===========
Effect of dilutive options and warrants 3,668,104 -- 3,497,262 --
----------- ----------- ----------- -----------
Fully diluted weighted average common
shares outstanding 62,137,376 52,610,356 61,352,899 50,382,455
=========== =========== =========== ===========
Basic earnings per share $ 0.01 $ (0.07) $ 0.11 $ (0.18)
=========== =========== =========== ===========
Fully diluted earnings per share $ 0.01 $ (0.07) $ 0.10 $ (0.18)
=========== =========== =========== ===========
For the three months and nine months ended September 30, 2003, the Company had
net losses. Only the weighted average of common shares outstanding has been used
to calculate both basic earnings per share and diluted earnings per share as
inclusion of the potential common shares would be anti-dilutive. For the three
months and nine months ended September 30, 2004, the Company had net income, and
excluded from the computation of fully diluted earnings per share are
outstanding common stock options and warrants with an exercise price greater
than the average market price of the common shares for such periods. For the
three and nine months ended September 30, 2004, the Company has excluded from
the fully diluted earnings per share computation 1,441,338 common shares.
The effect of approximately 3.4 million shares related to the assumed conversion
of the $95 million convertible senior subordinated debentures has been excluded
from the computation of diluted earnings per share for the three and nine months
ended September 30, 2004 as none of the conditions that would permit conversion
have been satisfied.
STOCK-BASED EMPLOYEE COMPENSATION
The Company accounts for stock-based employee compensation arrangements in
accordance with provisions of Accounting Principles Board (APB) Opinion No. 25,
"Accounting for Stock Issued to Employees." Compensation cost for stock options,
if any, is measured as the excess of the quoted market price of the stock at the
date of grant over the amount an employee must pay to acquire the stock. The
Company has adopted the disclosure only provisions of SFAS No. 123, "Accounting
for Stock-Based Compensation" and SFAS No. 148, "Accounting for Stock-Based
Compensation - Transition and Disclosure - An Amendment to FASB Statement No.
123."
Had compensation cost for the Company's Plans been determined based on the fair
value at the grant dates for the awards under a method prescribed by SFAS No.
123, the Company's income and earnings per share would have been decreased to
the pro forma amounts indicated below (in thousands, except per share amounts):
Three Months Ended Nine Months Ended
September 30, September 30,
------------------------- ----------------------
2004 2003 2004 2003
------- ------- ------- --------
Net income (loss), as reported $ 735 $(3,608) $ 6,272 $ (9,105)
Add: Stock-based employee compensation
included in reported net income,
net of related tax effects -- -- 87 --
Deduct: Total stock-based employee
compensation expense determined under
fair value based method for all awards,
net of related tax effects (2,171) (919) (5,170) (2,727)
Pro forma net income (loss)
$(1,436) $(4,527) $ 1,189 $(11,832)
Earnings per share:
Basic - as reported $ 0.01 $ (0.07) $ 0.11 $ (0.18)
Basic - pro forma $ (0.02) $ (0.07) $ 0.02 $ (0.18)
Diluted - as reported $ 0.01 $ (0.07) $ 0.10 $ (0.18)
Diluted - pro forma $ (0.02) $ (0.09) $ 0.02 $ (0.23)
6
The Company calculated the fair value of each option grant on the date of the
grant using Black-Scholes pricing method with the following assumptions for the
nine months ended September 30, 2004 and 2003: the dividend yield was 0% and 0%;
the weighted average expected option term was five years; risk-free interest
rate was 3.42% and 2.84%; and the stock volatility was 79% and 82%,
respectively. The weighted average fair value of options for September 30, 2004
and 2003 was $13.37 and $3.63, respectively.
The Company reports both basic earnings per share, which is based on the
weighted-average number of common shares outstanding, and diluted earnings per
share, which is based on the weighted-average number of common shares
outstanding and all dilutive potential common shares outstanding.
NOTE 2. Convertible Senior Subordinated Debentures
On April 5, 2004, the Company issued and sold $95.0 million in aggregate
principal amount of its 1.250% convertible senior subordinated debentures due
2024. The debentures were sold by the Company to Citigroup Global Markets Inc.,
Wachovia Capital Markets, LLC and First Albany Capital Inc., as initial
purchasers, in a private placement exempt from registration under the Securities
Act of 1933, as amended (the "Securities Act"). We have been advised by the
initial purchasers that they have resold, and/or intend in the future to resell,
the debentures to "qualified institutional buyers" (as defined in Rule 144A
promulgated under the Securities Act) in transactions exempt from the
registration requirements of the Securities Act in reliance on Rule 144A.
The issuance and sale of the debentures resulted in net proceeds to the Company
of approximately $91,388,000. These proceeds are being used for general
corporate purposes, including working capital requirements, manufacturing of our
products and research and development.
The debentures bear interest at the rate of 1.250% per year. Interest on the
debentures is payable on April 1 and October 1 of each year, beginning on
October 1, 2004. The debentures are convertible by holders into shares of our
common stock at a conversion price of $28.08 per share (which is subject to
adjustment upon certain events, but represented a 30% premium over our stock
price at the time the debentures were issued). The debentures are convertible by
holders into shares of our common stock if: (1) the price of our common stock
reaches a specific threshold; (2) the trading price for the debentures falls
below certain thresholds; (3) the debentures have been called for redemption; or
(4) certain corporate transactions occur.
The debentures mature on April 1, 2024, unless earlier redeemed, repurchased or
converted. Before April 5, 2007, we may redeem some or all of the debentures if
the price of our common stock reaches a specific threshold, at a redemption
price that includes an additional payment on the redeemed debentures equal to
$230.77 per $1,000 principal amount of debentures, less the amount of any
interest actually paid or accrued and unpaid on the debentures. On and after
April 5, 2007, the Company may redeem some or all of the debentures at certain
specified redemption prices.
The debentures are the Company's unsecured obligations and are subordinated in
right of payment to all of the Company's existing and future senior
indebtedness. On April 1, 2009, April 1, 2014, and April 1, 2019, and under
certain circumstances, holders of the debentures will have the right to require
us to repurchase all or any part of their debentures at a repurchase price equal
to 100% of the principal amount of the debentures, plus accrued and unpaid
interest and liquidated damages, if any, to, but excluding the repurchase date.
In September 2004, the FASB discussed EITF 04-08, "The Effect of Contingently
Convertible Debt on Diluted Earnings Per Share." The EITF has proposed that
companies count the shares that could be issued upon conversion of securities
like the Company's debentures when calculating fully diluted per share earnings.
Had EITF 04-08 been effective as of September 30, 2004, inclusion of the
3,383,188 common stock shares from the convertible debentures would be
anti-dilutive.
7
In connection with the offering of the debentures, we filed a shelf registration
statement in June 2004 with the SEC covering resales of the debentures and of
the common stock issuable upon conversion of the debentures. In September 2004,
the Company filed an amended shelf registration statement with the SEC relating
to the debentures. The registration statement was declared effective on Form S-3
on October 1, 2004.
NOTE 3. Recent Accounting Pronouncements
In January 2003, the FASB issued FASB Interpretation No. 46 (FIN 46),
"Consolidation of Variable Interest Entities." FIN 46 clarifies the application
of Accounting Research Bulletin No. 51, "Consolidated Financial Statements," to
certain entities in which equity investors do not have the characteristics of a
controlling financial interest or do not have sufficient equity at risk for the
entity to finance its activities without additional subordinated financial
support from other parties. FIN 46 applies immediately to variable interest
entities created after January 31, 2003, and to variable interest entities in
which an enterprise obtains an interest after that date. It applies in the first
fiscal year or interim period beginning after June 15, 2003, to variable
interest entities in which an enterprise holds a variable interest that it
acquired before February 1, 2003. FIN 46 applies to public enterprises as of the
beginning of the applicable interim or annual period. On October 8, 2003, the
FASB decided to defer FIN 46 until the first reporting period ending after
December 15, 2003. The provisions of this Interpretation did not have a material
impact on the Company's financial condition or results of operations.
In December 2003, the FASB issued FIN No. 46(R), "Consolidation of Variable
Interest Entities," clarifying the application of Accounting Research Bulletin
No. 51, "Consolidated Financial Statements," to certain entities in which equity
investors do not have the characteristics of a controlling financial interest or
do not have sufficient equity at risk for the entity to finance its activities
without additional subordinated financial support. The provisions of this
Interpretation did not have a material impact on the Company's financial
condition or results of operations.
In December 2003, the FASB revised SFAS 132, "Employers' Disclosure About
Pensions and Other Post Retirement Benefits." This Statement does not change the
measurement or recognition of those plans required by FASB No. 87, "Employers'
Accounting for Pensions," and No. 106, "Employers' Accounting for Post
Retirement Benefits Other than Pensions." This Statement retains the disclosure
requirements contained in FASB No. 132, "Employers' Disclosure about Pensions
and Other Post Retirement Plans." The provisions of this Statement did not have
a material impact on the Company's financial condition or results of operations.
During the nine months ended September 30, 2004 and 2003, the Company's
contributions to the 401-K Plan were $335,158 and $213,859, respectively.
In February 2004, the FASB issued revised FASB Staff Positions (FSP) pertaining
to FIN 46(R). The revised FSPs replace certain previously issued FIN 46 FSP for
entities to which FIN 46(R) is applicable. This revision to FIN 46 did not have
a material impact on the Company's financial condition or results of operation.
In February 2004, the FASB revised SFAS 133, "Accounting for Derivative
Instruments and Hedging Activities for Implementation Issue E2L, A1J, and C6."
The revisions to SFAS 133 did not have a material impact on the Company's
financial condition or results of operation.
In September 2004, the FASB discussed EITF 04-08, "The Effect of Contingently
Convertible Debt on Diluted Earnings Per Share." The EITF task force has
proposed that companies count the shares that could be issued upon conversion of
securities like the Company's debentures when calculating fully diluted per
share earnings. This EITF is not yet effective. However, we disclosed in Note 2
the potential effect of this EITF on the Company's fully diluted EPS
calculation.
NOTE 4. Our gross receivables and related deductions activity for the nine
months ended September 30, 2004 and 2003, and the year ended December 31, 2003
was:
8
Nine Months Ended Year Ended
----------------------- ------------
September 30, September 30, December 31,
(in $000s)
2004 2003 2003
------- ------- --------
Gross accounts receivable $26,545 $12,803 $ 17,091
Less: Accrued rebates (3,867) (2,429) (2,700)
Less: Accrued chargebacks (2,744) (2,377) (4,101)
Less: Other deductions (204) (98) (405)
------- ------- --------
Net accounts receivable $19,730 $ 7,899 $ 9,885
------- ------- --------
Other deductions include allowance for disputable items, doubtful accounts, and
cash discounts.
Net accounts receivable balance at September 30, 2004 includes $8,367,000 due
from Teva as compared to zero dollars at December 31, 2003.
Chargebacks and Rebates Accrual activity for the nine months ended September 30,
2004 and 2003, and the year ended December 31, 2003 was:
CHARGEBACKS ACCRUAL
-------------------
Nine Months Ended Year Ended
----------------------- ------------
(in $000s) September 30, September 30, December 31,
2004 2003 2003
------- ------- --------
Beginning Balance $ 4,101 $ 1,373 $ 1,373
Add: Provision related to sales made in current period 7,207 6,000 10,571
Less: Credits issued during the current period (8,564) (4,996) (7,843)
------- ------- --------
Ending Balance $ 2,744 $ 2,377 $ 4,101
------- ------- --------
REBATES ACCRUAL
---------------
Nine Months Ended Year Ended
----------------------- ------------
(in $000s) September 30, September 30, December 31,
2004 2003 2003
------- ------- --------
Beginning Balance $ 2,700 $ 1,525 $ 1,525
Add: Provision related to sales made in current period 4,441 4,857 6,680
Less: Credits issued during the current period (3,274) (3,953) (5,505)
------- ------- --------
Ending Balance $ 3,867 $ 2,429 $ 2,700
------- ------- --------
NOTE 5. Our inventory consists of the following:
September 30, December 31,
(in $000s) 2004 2003
------- --------
Raw materials $24,740 $ 9,671
Work in process 4,219 5,303
Finished goods 9,273 13,505
------- --------
$38,232 $ 28,479
======= ========
9
IMPAX, as do most companies in the generic pharmaceutical industry, may build
pre-launch inventories of certain ANDA-related products that have not yet
received FDA approval and/or satisfactory resolution of patent infringement
litigation when it believes that such action is appropriate to increase its
commercial opportunity and if Company's management believes that the approval is
pending in the near term. Because the ANDA is, in effect, a copy of the related
brand drug, we believe that there are no issues regarding safety and efficacy of
generic products. Pre-launch inventory is stated at the lower of cost or market.
Cost is determined using a standard cost method, which assumes a first-in,
first-out (FIFO) flow of goods. Costs of unapproved products are similar to the
approved products and include materials, labor, quality control, and production
overhead. Typically, the selling price of a generic pharmaceutical product is a
discount from the corresponding brand product selling price which is currently
marketed. In all cases, the pre-launch products have inventory costs lower than
their related net selling prices. If the market prices become lower than the
historical product costs, then the pre-launch inventory value will be written
down to market.
As of September 30, 2004, the Company's total inventory of $38,232,000 included
$2,848,000 in inventories relating to products pending launch while IMPAX awaits
receipt of FDA marketing approval and/or satisfactory resolution of patent
infringement litigation, as follows:
(in $000s) APPROVED UNAPPROVED TOTAL
-------- ---------- -------
Raw materials $ 23,318 $ 1,422 $24,740
Work in process 2,793 1,426 4,219
Finished goods 9,273 0 9,273
-------- ---------- -------
TOTAL $ 35,384 $ 2,848 $38,232
======== ========== =======
The major components of the unapproved inventory included approximately
$1,741,000 of Methylphenidate and approximately $737,000 of Riluzole (raw
materials only). The average remaining shelf life for Methylphenidate raw
material lots approximate thirty-five months and the work-in-process is
twenty-three months. The average remaining shelf life of Riluzole raw material
lots is approximately twenty-seven months. The remaining unapproved raw material
inventory includes products on which we expect approval in the next six months.
Typically, a generic drug is easily substituted for the corresponding brand
product and, once a generic product is approved, the pre-launch inventory is
sold within the first three months. If the inventory produced exceeds the
estimated market acceptance of the generic product and becomes short-dated, it
will be written-off. Raw materials generally have a shelf life of approximately
three to five years; finished products generally have a shelf life of
approximately twenty-four months. To our knowledge, as of the date of this
report, there are no manufacturing, marketing or labeling issues outstanding
related to unapproved inventory.
Approved inventory in the table above includes approximately $2,121,000 of
Oxycodone 80 mg tablets. The FDA has granted final approval to our ANDA for
Oxycodone. The patent litigation for this product is still ongoing. See
additional details in Part II, Item 1, Legal Proceedings for the current status
of this case.
Unapproved inventory of Riluzole is approximately $737,000 and the patent
litigation for this product is still ongoing. See additional details in Part II,
Item 1, Legal Proceedings for the current status of this case.
The Methylphenidate unapproved inventory is approximately $1,741,000 and does
not have any open patent litigation issues outstanding; however, IMPAX has not
received final FDA marketing approval.
When we believe that we are within approximately six months of receiving FDA
approval, we begin to schedule process validation studies as required by the FDA
to demonstrate the production process can be scaled up and reproduce commercial
batches.
NOTE 6. Intangibles consist of the following:
Estimated
(in $000s) useful life September 30, December 31,
(years) 2004 2003
----------- ------------ ------------
Product rights and licenses 3 - 8 $ 2,691 $ 2,691
Less: Accumulated amortization (2,600) (2,312)
------- ---------
$ 91 $ 379
======= =========
Amortization expense was $96,000 for the three months and $288,000 for the nine
months ended September 30, 2004, respectively. Expected amortization expense for
2004 will be approximately $379,000.
NOTE 7. ACCRUED EXPENSES AND DEFERRED REVENUE
Accrued expenses and deferred revenue as of September 30, 2004 and December 31,
2003 consist of the following:
10
September 30, December 31,
(in $000's) 2004 2003
------- -------
Sales returns $ 6,868 $ 4,121
Deferred revenues 1,767 1,751
Accrued salaries and payroll expenses 2,816 1,649
Legal and professional fees 2,028 1,478
Accrued Medicaid rebates 963 613
Accrued royalty and gross profit sharing expense 428 559
Accrued shelf stock reserve 130 232
Other accruals 336 469
------- -------
$15,336 $10,872
======= =======
NOTE 8. RETURNS ACCRUAL
Returns accrual as of September 30, 2004 and 2003, and December 31, 2003
consisted of the following:
RETURNS ACCRUAL
---------------
Nine Months Ended Year Ended
--------------------------- ----------
(in $000s) September 30, September 30, December 31,
2004 2003 2003
------- ------ -------
Beginning Balance $ 4,121 $3,100 $ 3,100
Add: Provision related to sales made in current period 4,914 709 2,276
Less: Credits issued during the current period (2,167) (709) (1,255)
------- ------ -------
Ending Balance $ 6,868 $3,100 $ 4,121
------- ------ -------
The returns accrual balance at September 30, 2004 includes $1,244,000 for
products marketed through Rx Partners, i.e., Teva, as compared to zero dollars
at December 31, 2003. As our product sales continue to increase, the provision
for sales returns will also continue to increase.
The sales returns reserve increased by $3,768,000 for the nine months ended
September 30, 2004 as compared to the same period in 2003. This significant
increase in the reserve balance related to the Teva products reserve of
$1,244,000, an increase in Lipram product reserve of approximately $1,087,000,
and Orphenadrine product reserve of approximately $2,414,000, which was
partially offset by a decrease in the product reserve for Fludrocortisone of
approximately $1,010,000. The new product returns reserve calculation is a
weighted percentage based on limited historical data.
The Lipram product family is not AB rated (products that demonstrated
bioequivalence with innovator products) and is not manufactured by IMPAX, but it
is packaged and distributed by us. On average, we ship Lipram products with
approximately seven months of dating remaining. This can be attributed to both
the vendor (sending product with less than full dating) and our internal
packaging priorities. Limited dating, combined with the slow moving nature of
these non-AB rated products, create more returns exposure for this product
family. Please note that we are monitoring returns by product and, where
applicable, we establish specific product returns reserves and/or adjust our
estimates of the future return rates based on various business and competitive
assumptions.
We instituted an inventory management program for our wholesale customers.
Through this program, we use on-hand and usage data from the wholesalers in the
form of monthly pipeline inventory reports to help govern fulfillment of
purchase orders. This also has helped to keep our returns exposure down by
decreasing the potential for expired material on the customers' shelves.
NOTE 9. COMMITMENTS AND CONTINGENCIES
Patent Litigation
The Company is a defendant in several lawsuits with respect to the manufacture,
use, and sale of new products that are the subject of conflicting patent rights.
In general, one or more patents tend to cover the brand name controlled-release
products for which we are developing generic versions. Under the Hatch-Waxman
Amendments, when a drug developer files an ANDA for a generic drug, and the
developer believes that an unexpired patent which has been listed with the FDA
as covering that brand name product will not be infringed by the developer's
product or is invalid or unenforceable, the developer must so certify to the
11
FDA. That certification must also be provided to the patent holder, who may
challenge the developer's certification of non-infringement, invalidity or
unenforceability by filing a suit for patent infringement within 45 days of the
patent holder's receipt of such certification. If the patent holder files suit,
the FDA can review and tentatively approve the ANDA, but is prevented from
granting final marketing approval of the product until a final judgment in the
action has been rendered, or 30 months from the date the certification was
received, whichever is sooner. Should a patent holder commence a lawsuit with
respect to an alleged patent infringement by us, the uncertainties inherent in
patent litigation make the outcome of such litigation difficult to predict. Even
if the FDA were to approve a product upon expiration of the 30-month period, we
may not commence marketing that product if patent litigation is still pending.
The Company's policy is that it does not market its generic version of a brand
product until the Company has both final FDA approval and some indication of the
patent status from the courts, unless it secures some form of indemnification
from a strategic partner or obtains risk mitigation insurance. As a result, the
Company, generally, does not have any risk of loss relating to patent
infringement lawsuits. According to FAS No. 5, there are two conditions that
must be met for an estimated loss from a loss contingency to be accrued as a
charge to income: a) information available prior to issuance of the financial
statements indicates that it is probable that an asset had been impaired or a
liability had been incurred at the date of the financial statements, and b) the
amount of loss can be reasonably estimated. The Company believes that these
conditions are not satisfied because no liability was incurred or recognized, as
a loss is not probable and cannot be reasonably estimated, since the Company's
policy is not to market its products until it receives both final FDA approval
and some indication of the patent status from the courts. However, if IMPAX
decides to market the product before the patent status is cleared by the courts,
the Company will then evaluate its liability and separately assess recovery, if
any, from the indemnification arrangement with strategic partners or risk
mitigation insurance.
As part of our patent litigation strategy, we obtained two policies covering up
to $7 million of patent infringement liability insurance from American
International Specialty Line Company ("AISLIC"), an affiliate of AIG
International. This litigation insurance covered us against the costs associated
with patent infringement claims made against us relating to seven of the ANDAs
we filed under Paragraph IV of the Hatch-Waxman Amendments. Both policies have
reached their limit of liability. While Teva has agreed to pay 45% to 50% of the
attorneys' fees and costs (in excess of the $7 million covered by our insurance
policies) related to the twelve products covered by our strategic alliance
agreement with Teva, we will be responsible for the remaining expenses and costs
for these products, and all of the costs associated with patent litigation for
our other products and our future products.
We do not believe that this type of litigation insurance will be available on
acceptable terms for our current or future ANDAs. In those cases, our policy is
to record such expenses as incurred.
Although the outcome and costs of the asserted and unasserted claims is
difficult to predict because of the uncertainties inherent in patent litigation,
management does not expect the Company's ultimate liability for such matters to
have a material adverse effect on its financial condition, results of
operations, or cash flows.
FIN 45
In November 2002, the FASB issued FIN 45, "Guarantor's Accounting and Disclosure
Requirements for Guarantees, Including Indirect Guarantees of Indebtedness of
Others." Guarantees and claims arise during the ordinary course of business from
relationships with suppliers, customers, and strategic partners when the Company
undertakes an obligation to guarantee the performance of others through the
delivery of cash or other assets if specified triggering events occur.
Non-performance under a contract by the guaranteed party triggers the obligation
of the Company. As of September 30, 2004, all indemnifications included in
agreements as of that date are excluded from the scope of FIN 45 as they relate
primarily to our own future performance and do not require any contingent
payments.
As of September 30, 2004, our total contractual commitments on loans, operating
leases, and royalty agreements have not materially changed since December 31,
2003, as disclosed in our Report on Form 10-K.
NOTE 10. LOAN AGREEMENTS WITH PIDA AND DRPA
In April 2004, the Company terminated the loan agreements with Pennsylvania
Industrial Development Authority (PIDA) and Delaware River Port Authority (DRPA)
and repaid the remaining balances totaling approximately $992,000.
NOTE 11. LOAN AND SECURITY AGREEMENT WITH WACHOVIA BANK N.A.
In June 2004, the $25 million Loan and Security Agreement with Wachovia Bank
N.A. was amended, as follows:
o The cash collateral requirement of $10,000,000 was removed.
o The adjusted excess availability covenant was removed.
o IMPAX will maintain at Wachovia Bank cash and investments in an amount
not less than $25,000,000.
12
o If the amount of cash and investments decline below $25,000,000, then
the cash collateral requirement of $10,000,000 and adjusted excess
availability covenant will be re-established.
o If the Company reports negative free cash flow in any quarter, then
reserves in the amount of the negative free cash flow will be reported
in the borrowing base.
o The maximum aggregate capital expenditures permitted during any fiscal
year in the amount of $8,000,000 was amended to permit a maximum
cumulative aggregated amount of $45,000,000 for fiscal years 2004 and
2005.
NOTE 12. INCOME TAXES
On a quarterly basis, the Company evaluates its projected full year taxable
income and related book-to-tax timing difference and the use of net operating
loss (NOL) carryforwards. The Company estimates that it is not subject to
current year income taxes. As of September 30, 2004, the Company had net
operating loss carryforwards aggregating approximately $112 million expiring
from 2009 through 2023. We evaluate the realizability of deferred tax assets on
an annual and quarterly basis or if there is a significant change in
circumstance that may cause a change in our judgment about the realizability of
our deferred tax assets.
NOTE 13. SEGMENT INFORMATION
SFAS No. 131, "Disclosures About Segments of an Enterprise and Related
Information" establishes standards for reporting of financial information about
operating segments in annual and quarterly financial statements. The Company
manufactures generic pharmaceutical products. All products have similar
characteristics from development, customer demographics, and operating points of
view, and are approved by the FDA under the ANDA process described in Note 9 of
this Form 10-Q report. Because of the characteristics mentioned above and how we
manage our operations, the Company has one reportable operating segment: generic
pharmaceutical business. However, we currently market our products through three
different channels, as follows:
o Direct sale of prescription (Rx) products, such as LIPRAM,
Fludrocortisone, Terbutaline, Minocycline, Demeclocycline, Flavoxate,
Carbidopa/Levodopa and others, through our Global Pharmaceuticals
division, called "Global";
o Sale of prescription (Rx) products, such as Bupropion Hydrochloride and
Omeprazole, exclusively, through marketing partners, pursuant to
strategic alliance agreements, such as Teva, called "Rx Partners;" and
o Sale of Loratadine OTC products through marketing partners, pursuant to
strategic alliance agreements, such as Schering, Wyeth, Novartis, and
Leiner, called "OTC."
The following table summarizes the net sales for the three and nine months ended
September 30, 2004 as compared to the three and nine months ended September 30,
2003 by marketing channel:
Three Months Ended Nine Months Ended
September 30, September 30,
---------------------------- ---------------------------
2004 2003 2004 2003
-------- -------- -------- --------
(in $000's)
Global $ 14,617 $ 10,184 $ 40,451 $ 27,049
Rx Partners 10,795 -- 38,708 --
OTC 4,849 5,724 12,639 13,385
-------- -------- -------- ---------
Total Net Sales $ 30,261 $ 15,908 $ 91,798 $ 40,434
======== ======== ======== ========
ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS
OF OPERATIONS
This report contains forward-looking statements within the meaning of Section
27A of the Securities Act of 1933, as amended, and Section 21E of the Securities
Exchange Act of 1934, as amended. Forward-looking statements include statements
about our business strategies, our expected financial position and operating
results, the projected size of our markets and our financing plans and similar
matters. The words "believe," "expect," "intend," "anticipate," "plan," "may,"
"will," "could," "should," "estimate," "potential," "opportunity," "future,"
"project," "forecast," and similar expressions, as they relate to us, our
management and our industry are intended to identify forward-looking statements.
We have based these forward-looking statements largely on our current
expectations and projections about future events and financial trends affecting
the financial condition of our business. These forward-looking statements
involve known and unknown risks and uncertainties. Our actual results could
differ materially from the results discussed in the forward-looking statements.
You should not place undue reliance on our forward-looking statements. Further,
any forward-looking statement speaks only as of the date on which it is made,
and we undertake no obligation to update or revise any forward-looking
statements for any reason, whether as a result of new information, future
developments or otherwise.
13
Many factors could cause or contribute to a material change from the results
discussed in the forward-looking statements. Such factors include, in no
particular order:
o our ability to successfully develop and commercialize additional
products;
o changes in the degree of competition for our products;
o the difficulty of predicting FDA and other regulatory authority
approvals;
o our reliance on strategic alliances and the success of such strategic
alliances;
o the inability to acquire sufficient supplies of raw materials;
o litigation and/or threats of litigation;
o changes in our growth rates or the growth rates of our competitors;
o legislative and FDA actions with respect to the government regulation of
pharmaceutical products;
o public concern as to the safety of our products;
o changes in health care policy in the United States;
o conditions in the financial markets in general or in general economic
conditions;
o our inability to raise additional capital when needed;
o the impact of competition from brand-name companies that sell their own
generic products or successfully extend the exclusivity period of their
branded products;
o the difficulty in predicting the timing and outcome of legal
proceedings, including patent-related matters such as patent
infringement cases and patent challenge settlements;
o court and FDA decisions on exclusivity periods under the Hatch-Waxman
Amendments;
o our dependence on revenues from significant customers;
o our dependence on revenues from significant products; and
o the increasing cost of insurance and the availability of product
liability insurance coverage.
GENERAL
Impax Laboratories, Inc. was formed through a business combination on December
14, 1999 between Impax Pharmaceuticals, Inc., a privately held drug delivery
company, and Global Pharmaceutical Corporation, a generic pharmaceutical
company. Impax Pharmaceuticals, Inc. merged with and into Global, with Impax
stockholders receiving 3.3358 shares of Global common stock for each share of
Impax Pharmaceuticals, Inc. At the conclusion of the merger, Impax
Pharmaceuticals, Inc. stockholders held over 70% of the combined company. For
accounting purposes, the merger has been treated as a recapitalization of Impax
Pharmaceuticals, Inc. with Impax Pharmaceuticals, Inc. deemed the acquirer of
Global in a reverse acquisition. As a reverse acquisition, our historical
operating results prior to the merger are those of Impax Pharmaceuticals, Inc.
and only include the operating results of Global after the merger. In connection
with the merger, the surviving company changed its name to Impax Laboratories,
Inc.
We are a technology based, specialty pharmaceutical company applying formulation
and development expertise, as well as our drug delivery technology, to the
development of controlled-release and niche generics, in addition to the
development of branded products. As of September 30, 2004, the Company marketed
thirty-three generic pharmaceuticals, which represent dosage variations of
fourteen different pharmaceutical compounds, and has fourteen applications under
review with the FDA, including four tentatively approved, addressing
approximately $4.3 billion in U.S. product sales in the twelve months ended
August 31, 2004, according to NDCHealth. Nine of these pending filings were
filed under Paragraph IV of the Hatch-Waxman Amendments. The Company has
approximately twenty-five other products in various stages of development for
which applications have not yet been filed. These other products are generic
versions of pharmaceutical products that had U.S. sales of approximately $15.6
billion in the twelve months ended August 31, 2004, according to NDCHealth.
The Drug Price Competition and Patent Term Restoration Act of 1984, referred to
as the Hatch-Waxman Amendments, established an abbreviated new drug application
procedure for obtaining FDA approval of generic versions of certain drugs. An
ANDA is similar to a new drug application, sometimes referred to as an NDA,
except that the FDA waives the requirement that the applicant conduct and submit
to the FDA clinical studies to demonstrate the safety and effectiveness of the
drug. Instead, for drugs that contain the same active ingredient and are of the
same route of administration, dosage form, strength and indication(s) as drugs
already approved for use in the United States, the FDA ordinarily only requires
bioavailability data demonstrating that the generic formulation is bioequivalent
to the previously approved reference listed drug, indicating that the rate of
absorption and the levels of concentration of the generic drug in the body do
not show a significant difference from those of the previously approved
reference listed drug product. According to information published by the FDA,
the FDA currently takes approximately 18 to 20 months on average to approve an
ANDA following the date of its first submission to the FDA.
14
Patent certification requirements for generic drugs could also result in
significant delays in obtaining FDA approvals. First, where patents covering a
reference listed drug are alleged to be invalid, unenforceable, or not infringed
by an ANDA applicant, the holder or holders of the brand name drug patents may
institute patent infringement litigation and obtain a stay of up to 30 months of
approval of an ANDA, and for ANDAs of products whose patent information was
listed before August 2003, potentially multiple 30 month stays. Second, the
first company to submit an ANDA for a given drug, which the FDA accepts for
filing, and which certifies that an unexpired patent covering the reference
listed brand name drug is invalid, unenforceable, or will not be infringed by
its product, can be awarded 180 days of market exclusivity following approval of
its ANDA, during which the FDA may not approve any other ANDAs for that drug
product.
CRITICAL ACCOUNTING POLICIES
Revenue Recognition
-------------------
A substantial part of the Company's sales are made to prescription drug
wholesalers that call for delivery of our products. Additionally, we have
entered into various agreements that contain multiple elements in which we have
received up front fees, milestone payments, and/or royalties. Milestone revenues
from our strategic alliances are recognized on a straightline basis over the
term of the contract.
The Company recognizes revenue in accordance with SAB 101 issued by the SEC in
December 1999. We recognize revenue from the sale of products when the shipment
of products is received and accepted by the customer. Provisions for estimated
discounts, rebates, chargebacks, returns and other adjustments are provided for
in the period the related sales are recorded. In December 2003, SAB 104 was
issued by the SEC. This bulletin clarifies portions of Topic 13 of the Staff
Accounting Bulletin to be consistent with current accounting and auditing
guidance and SEC rules and regulations and revises accounting guidance contained
in SAB 101 related to multiple element revenue arrangements of EITF No. 00-21
superseded as a result of the issuance.
EITF No. 00-21 supplemented SAB 101 for accounting for multiple element
arrangements. The Company has entered into several strategic alliances that
involve the delivery of multiple products and services over an extended period
of time. In multiple element arrangements, the Company must determine whether
any or all of the elements of the arrangement can be separated from one another.
If separation is possible, revenue is recognized for each deliverable when the
revenue recognition criteria for the specific deliverable is achieved. If
separation is not possible, revenue recognition is required to be spread over an
extended period.
Under EITF No. 00-21, in an arrangement with multiple elements, the delivered
item should be considered a separate unit of accounting if all of the following
criteria are met:
1) the delivered item has value to the customer on a standalone basis;
2) there is objective and reliable evidence of the fair value of the
undelivered item; and
3) if the arrangement included a general right of return, whether delivery
or performance of the undelivered item is considered probable.
The Company reviews all of the terms of its strategic alliances and follows the
guidance from SAB 104 and EITF No. 00-21 for multiple element arrangements.
Upfront and milestone payments from these strategic alliances are deferred and
recognized over the life of the agreements as the Company fulfills its
contractual obligation to manufacture and supplies products during this period.
In addition, in some agreements, the Company receives and records royalty
revenue based on a percentage of the strategic partner's total sales to their
customers of the products supplied by IMPAX.
In June 2001, the Company entered into a Strategic Alliance Agreement with a
subsidiary of Teva for twelve controlled-release generic pharmaceutical
products. The agreement granted Teva exclusive U.S. prescription marketing
rights for these products for a period of ten years from the date of Teva's
first sale of the products.
The Company believes it is important for the users of its financial statements
to understand the key components, which reduce gross sales to net sales.
Returns Reserve
---------------
The Company estimates future product returns at the time of sale. Product
returns by wholesalers principally relate to the return of expired products. For
product return reserves, we consider volume and mix of product in the
marketplace, historical return rates, and the competitive environment, all of
which require us to use estimates and assumptions. IMPAX introduces a number of
new products each year. As a result, the Company has been able to monitor
historical return rates for new products. Based on our historical data, because
15
we have one business segment, we have found that generic pharmaceutical product
returns are alike and that new product returns have similar characteristics to
existing products returns. Usually, new products are AB rated (products that
demonstrated bioequivalence with innovator products), have 24 month expiration
dating, and are marketed to the same customers, i.e., wholesalers, warehousing
chains, and distributors. The AB rated products are substitutable by the
pharmacist for the innovator products. The non-AB rated products, such as the
LIPRAM product family, generally, may not be substituted by the pharmacist as
they are therapeutic alternatives, not generic substitutes. Any change to a
patient's prescription to an alternative product requires the patient's
physician approval for the substitution. We are monitoring returns by product
and, where applicable, we establish specific product return reserves and/or
adjust our estimates of the future return rates based on various business and
competitive assumptions.
The sales return reserve is calculated using an historical lag period (the time
between when the product is sold and when it is ultimately returned as
determined from the Company's system generated lag period report) and return
rates, adjusted by estimates of the future return rates based on various
assumptions, which may include changes to internal policies and procedures,
changes in business practices and commercial terms with customers, competitive
position of each product, amount of inventory in the pipeline, the introduction
of new products, and changes in market sales information. In addition, when we
become aware of any excess inventory on hand at wholesalers, we reduce the
revenue initially recognized to zero dollars for this inventory. For the quarter
ended September 30, 2004 we did not become aware of any excess inventory on hand
at wholesalers.
Our returned goods policy requires prior authorization for the return, with
corresponding credits being issued at the current invoice prices, less amounts
previously granted to the customer for rebates and chargebacks. Products
eligible for return must be expired and returned within one year following the
expiration date of the product. Prior to 2002, we required returns of products
within six months of expiration date. Because of the lengths of the lag period
and volatility that may occur from quarter to quarter, we are currently using a
rolling 23-month calculation to estimate our product return rate.
We are also estimating returns for products marketed by our Rx Partners based on
our internal returns analysis and historical industry statistics.
The reserve for sales returns for new products as of December 31, 2003, and for
September 30, 2004, was $387,000, and $1,951,000 (which included $1,244,000
sales returns reserve for products marketed by Teva), respectively.
The Company believes that its estimated returns reserves were adequate at each
balance sheet date since they were formed based on the information that was
known and available, and were supported by the Company's historical experience
when similar events occurred in the past, and management's overall knowledge of
and experience in the generic pharmaceutical industry. In estimating its returns
reserve, the Company looks to returns after the balance sheet date, but prior to
filing its financial statements to ensure that any unusual trends are
considered.
Rebates and Chargebacks
-----------------------
Generally, sales rebates are calculated at the point of sale, based on
pre-existing written customer agreements by product and accrued on a monthly
basis. However, we do estimate additional rebates for specific purposes, i.e.,
new pharmacy store openings.
The vast majority of chargebacks are also calculated at the point of sale as the
difference between list price and contract price by product (with the
wholesalers) and accrued on a monthly basis. There are additional chargebacks
that are estimated at the point of sale to the wholesaler as the difference
between the wholesalers' contract price and the Company's contract price with
retail pharmacies and buying groups.
Shelf-Stock Reserve
-------------------
A reserve is estimated at the point of sale for certain products for which it is
probable that shelf-stock credits will be granted to customers for inventory
remaining on their shelves following a decrease in the market price of these
products. When estimating this reserve, we consider the competitive products,
the estimated decline in market prices, and the amount of inventory in the
pipeline.
Inventory
---------
Our inventories are valued at the lower of cost or market. Costs are determined
using a standard cost method, first-in, first-out (FIFO) flow of goods. Costs
include materials, labor, quality control and production overhead. We review and
adjust inventory for short-dated product and inventory commitments under supply
agreements based on projections of future sales and market conditions. The
Company, like most companies in the generic pharmaceutical industry, may build
inventories of certain ANDA-related products that have not yet received FDA
approval and/or satisfactory resolution of patent infringement litigation, when
it believes that such action is appropriate to increase its commercial
opportunity. Because the ANDA is, in effect, a copy of the related brand drug,
we believe that there are no issues regarding safety and efficacy of generic
products. If our inventory is greater than estimated shipments to our customers,
there may be an inventory write-down. Therefore, the Company's management must
make significant estimates relating to inventory.
16
Impaired Assets
---------------
The Company evaluates the carrying value of long-lived assets to be held and
used, including definite lived intangible assets, on an annual basis, when
events or changes in circumstances indicate that the carrying value may not be
recoverable. The carrying value of a long-lived asset is considered impaired
when the total projected undiscounted cash flows from such asset is separately
identifiable and is less than its carrying value. In that event, a loss is
recognized based on the amount by which the carrying value exceeds the fair
value of the long-lived asset. Fair value is determined primarily using the
projected cash flows discounted at a rate commensurate with the risk involved.
Losses on long-lived assets to be disposed of are determined in a similar
manner. As the Company's assumptions related to assets to be held and used are
subject to change, additional write-downs may be required in the future.
Goodwill
--------
Prior to the adoption of SFAS No. 142, "Goodwill and Other Intangible Assets,"
we amortized goodwill on a straight-line basis over its estimated useful life.
The Company adopted the provisions of SFAS No. 142, effective January 1, 2002;
no impairment was noted. Under the provisions of SFAS No. 142, the Company
performs the annual review for impairment at the reporting unit level, which the
Company has determined to be consistent with its business segment, that is, the
entire Company.
Effective January 1, 2002, we evaluated the recoverability and measured the
possible impairment of our goodwill under SFAS No. 142. The impairment test is a
two-step process that begins with the estimation of the fair value of the
reporting unit. The first step screens for potential impairment and the second
step measures the amount of the impairment, if any. Our estimate of fair value
considers publicly available information regarding the market capitalization of
our Company, as well as (i) publicly available information regarding comparable
publicly-traded companies in the generic pharmaceutical industry, (ii) the
financial projections and future prospects of our business, including its growth
opportunities and likely operational improvements, and (iii) comparable sales
prices, if available.
As part of the first step to assess potential impairment, we compare our
estimate of fair value for the Company to the book value of our consolidated net
assets. If the book value of our net assets is greater than our estimate of fair
value, we would then proceed to the second step to measure the impairment, if
any.
The second step compares the implied fair value of goodwill with its carrying
value. The implied fair value is determined by allocating the fair value of the
reporting unit to all of the assets and liabilities of that unit as if the
reporting unit had been acquired in a business combination, and the fair value
of the reporting unit was the purchase price paid to acquire the reporting unit.
The excess of the fair value of the reporting unit over the amounts assigned to
its assets and liabilities is the implied fair value of goodwill. If the
carrying amount of the reporting unit goodwill is greater than its implied fair
value, an impairment loss will be recognized in the amount of the excess.
On a quarterly basis, we perform a review of our business to determine if events
or changes in circumstances have occurred which could have a material adverse
effect on the fair value of the Company and its goodwill. If such events or
changes in circumstances were deemed to have occurred, we would consult with one
or more valuation specialists in estimating the impact on our estimate of fair
value. We believe the estimation methods are reasonable and reflective of common
valuation practices. We perform our annual goodwill impairment test in the
fourth quarter of each year.
RESULTS OF OPERATIONS
Except for the first, second and third quarters of 2004, we have incurred net
losses in each quarter since our inception. We had an accumulated deficit of
$98,277,000 at September 30, 2004.
THREE MONTHS ENDED SEPTEMBER 30, 2004 COMPARED TO THREE MONTHS ENDED
SEPTEMBER 30, 2003
OVERVIEW
The net income for the three months ended September 30, 2004, was $735,000 as
compared to a net loss of $3,608,000 for the three months ended September 30,
2003.
REVENUES
Total Revenues for the third quarter of 2004 were $30,704,000, up more than 86%
compared with revenues of $16,497,000 in the prior year's third quarter and
slightly higher sequentially from the total revenue of $30.6 million in the
second quarter of 2004. The year-over-year increase for the quarter was
primarily due to shipments of our generic versions of Wellbutrin(R) SR
(Declomycin(R) (Demeclocycline Hydrochloride) 150 mg and 300 mg Tablets, which
commenced during the first quarter of 2004; and Zyban(R) (Bupropion
Hydrochloride) and Sinemet(R) CR (Carbidopa/Levodopa) Extended Release Tablets,
which commenced during the second quarter of 2004. During the 2004 third
quarter, IMPAX's revenues from product shipments through our strategic alliance
agreements with Teva and Andrx, were approximately $10,795,000, compared with
$8,347,000 in the second quarter of 2004.
17
The balance of $443,000 of other revenue represents revenues recognized pursuant
to strategic agreements with Schering-Plough, Wyeth, Novartis, and Leiner. These
amounts represent the amortization of the milestone payments received by the
Company over the life of the agreements. The following table summarizes the
activity in net revenues for the three months ended September 30, 2004 and 2003:
Three Months Ended
September 30,
----------------------
2004 2003
------- -------
(in 000's)
Product sales $34,651 $21,628
Less:
Rebates (1,114) (2,054)
Chargebacks (1,245) (2,646)
Product return reserve (1,041) (389)
Other credits (990) (631)
------- -------
Net sales 30,261 15,908
Other Revenues 443 589
------- -------
Total Revenues $30,704 $16,497
======= =======
For chargebacks and rebates, refer to Note 4; for product returns reserve, refer
to Note 8.
The rebates, chargebacks, returns and other credits decreased for the
three months ended September 30, 2004 to approximately 13% of product
sales as compared to approximately 26% for the comparable period in 2003.
This decrease was mainly due to Bupropion Hydrochloride) 100 mg and 150 mg
Controlled Release Tablets, and Loratadine and Pseudoephedrine Sulfate
(5mg/120mg) 12-hour Extended Release Tablets. The Loratadine and
Pseudoephedrine Sulfate (5mg/120mg) 12-hour Extended Release Tablets are
exempt from rebates, chargebacks and other credits as per the agreements
with Schering-Plough and Wyeth. The product sales reported by Teva to
IMPAX are net of rebates, chargebacks and other credits as per the June
2001 Strategic Alliance Agreement. We began estimating returns for
products marketed by our Rx Partners, such as Teva, based on our internal
returns analysis and historical industry statistics.
Currently, the Company has one reportable operating segment: generic
pharmaceutical business. However, we currently market our products through three
different channels, as follows:
o Direct sale of prescription (Rx) products, such as LIPRAM,
Fludrocortisone, Terbutaline, Minocycline, Demeclocycline, Flavoxate,
Carbidopa/Levodopa and others, through our Global Pharmaceuticals
division, called "Global";
o Sale of prescription (Rx) products, such as Bupropion Hydrochloride and
Omeprazole, exclusively, through marketing partners, pursuant to
strategic alliance agreements, such as Teva, called "Rx Partners;" and
o Sale of Loratadine OTC products through marketing partners, pursuant to
strategic alliance agreements, such as Schering, Wyeth, Novartis, and
Leiner, called "OTC."
The following table summarizes the net sales for the three months ended
September 30, 2004 compared to the three months ended September 30, 2003 by
marketing channel:
Three Months Ended
September 30,
----------------------
2004 2003
------- -------
(in 000's)
Global $14,617 $10,184
Rx Partners 10,795 --
OTC 4,849 5,724
------- -------
Total Net Sales $30,261 $15,908
======= =======
18
The 2004 third quarter increase of approximately $4.4 million in Global products
over 2003 third quarter was primarily due to new products introduced in 2004 and
late 2003, such as Demeclocycline, with net sales of approximately $2.7 million,
Carbidopa/ Levodopa, with net sales of approximately $2.1 million, Orphenadrine,
with net sales of approximately $1.0 million, and Flavoxate, with net sales of
approximately $0.7 million, and was partially offset by lower sales of
Fludrocortisone of approximately $1.7 million.
The Rx Partners year-over-year increase for the third quarter of 2004 was
primarily due to shipments of our generic versions of Wellbutrin(R) SR
(Bupropion Hydrochloride) 100 mg and 150 mg Controlled Release Tablets, which
commenced shipment in the first quarter of 2004, and Zyban(R) (Bupropion
Hydrochloride) 150 mg Extended Release Tablets, which commenced shipment during
the second quarter of 2004. The OTC products sales decreased by approximately
$875,000 from the same period in the prior year due, primarily, to the timing of
the initial launch in 2003.
Rollforward analyses for each significant revenue dilution item are listed on
Note 4 and Note 8.
COST OF SALES
The cost of sales for the three months ended September 30, 2004 was $17,592,000
as compared to $12,976,000 for the same period in 2003. The overall increase in
cost of sales was primarily due to the increase in cost of materials as a result
of increased product sales and approximately $450,000 of various production
batches written-off, of which $33,000 was for new products. This includes
approximately $7,000 for Omeprazole capsules and approximately $26,000 for
Loratadine and Pseudoephedrine D-24, which were manufactured as part of the
validation manufacturing transition effort. The estimated plant capacity
utilization during the three months ended September 30, 2004 approximated 71% of
total capacity available and we expect to have excess capacity in the fourth
quarter of 2004. The full plant capacity utilization in 2005 is highly dependent
on new product approvals. At this time, we cannot project the effect of
potential excess capacity on future operations and liquidity.
GROSS MARGIN
Gross margin for the three months ended September 30, 2004 was $13,112,000, or
approximately 43% of total revenues, compared with gross margin of $3,521,000,
or approximately 21% of total revenues, in the prior year's third quarter. The
year-over-year increase in the gross margin percentage was primarily due to the
introduction of new products since last year with higher margins, such as
Bupropion Hydrochloride, Demeclocycline Hydrochloride, Flavoxate, and
Carbidopa/Levodopa.
RESEARCH AND DEVELOPMENT EXPENSES
The research and development expenses for the three months ended September 30,
2004 were $4,942,000 less reimbursements of $217,000 by a subsidiary of Teva
under the Strategic Alliance Agreement signed in June 2001, as compared to
$3,358,000 less reimbursements of $93,000 for the same period in 2003. The
increase in research and development expenditures in 2004 as compared to 2003
was primarily attributable to higher personnel costs of approximately $481,000,
clinical studies of approximately $412,000, biostudies of approximately
$350,000, supplies of approximately $92,000 and new product introduction costs
of approximately $72,000.
PATENT LITIGATION COSTS
The patent litigation expenses for the three months ended September 30, 2004,
were $3,299,000 as compared to $845,000 for the same period in 2003. The
year-to-year increase for the three months was primarily due to the ongoing
Paragraph IV litigation related to our ANDAs for Omeprazole Capsules,
Fenofibrate Tablets, Fexofenadine and Pseudoephedrine Tablets, Oxybutynin
Tablets and generic Adderall Capsules. The 2003 expense was partially offset by
AIG patent litigation insurance payments.
SELLING EXPENSES
The selling expenses for the three months ended September 30, 2004 were $908,000
as compared to $546,000 for the same period in 2003. The increase in selling
expenses as compared to 2003 was primarily due to new leased office expense of
approximately $124,000, higher personnel costs of approximately $106,000,
advertising of approximately $42,000, selling sheets of approximately $21,000,
and freight costs of approximately $29,000.
GENERAL AND ADMINISTRATIVE EXPENSES
The general and administrative expenses for the three months ended September 30,
2004 were $3,289,000 as compared to $2,321,000 for the same period in 2003. The
increase in general and administrative expenses as compared to 2003 was
primarily due to higher insurance premiums of approximately $645,000 and
personnel costs of approximately $536,000.
19
INTEREST INCOME
Interest income for the three months ended September 30, 2004 was $387,000 as
compared to $87,000 for the same period in 2003, primarily due to higher average
cash equivalents and short-term investments generated from the net proceeds of
the Company's offering of $95 million convertible senior subordinated debentures
issued in April 2004.
INTEREST EXPENSE
Interest expense for the three months ended September 30, 2004 was $547,000 as
compared to $243,000 for the same period in 2003. The increase in the interest
expense for 2004 was primarily due to the 1.25% interest accrued on the
Company's $95 million convertible senior subordinated debentures.
INCOME TAXES
On a quarterly basis, the Company evaluates its projected full year taxable
income and related book-to-tax timing difference and the use of NOL
carryforwards. The Company estimates that it is not subject to current year
income taxes. We evaluate the realizability of deferred tax assets on an annual
and quarterly basis or if there is a significant change in circumstance that may
cause a change in our judgment about the realizability of our deferred tax
assets. As of September 30, 2004, the Company had net operating loss
carryforward aggregating approximately $112 million expiring from 2009 through
2023.
NET INCOME
The net income for the three months ended September 30, 2004 was $735,000 as
compared to a net loss of $3,608,000 for the same period in 2003, primarily due
to higher revenues and gross margins, partially offset by the increases in
research and development, patent litigation, selling and general and
administrative expenses.
NINE MONTHS ENDED SEPTEMBER 30, 2004, COMPARED TO NINE MONTHS ENDED
SEPTEMBER 30, 2003
OVERVIEW
The net income for the nine months ended September 30, 2004 was $6,272,000 as
compared to a net loss of $9,105,000 for the nine months ended September 30,
2003.
REVENUES
Total Revenues for the nine months ended September 30, 2004 were $95,813,000 up
more than 128% compared with revenues of $41,989,000 in the comparable period of
the previous year. The year-over-year increase for the nine months was primarily
due to shipments of our generic versions of Wellbutrin(R) SR (Bupropion
Hydrochloride) 100 mg and 150 mg Controlled Release Tablets, and Declomycin(R)
(Demeclocycline Hydrochloride) 150 mg and 300 mg Tablets, which commenced during
the first quarter of 2004, and Zyban(R) (Bupropion Hydrochloride) and Sinemet(R)
CR (Carbidopa/Levodopa) Extended Release Tablets, which commenced during the
second quarter of 2004, as well as shipments of Flavoxate and Orphenadrine.
The Company generated $4,015,000 of other revenues in the 2004 period compared
to $1,555,000 in the 2003 period. Other revenue for the 2004 period included
$2,500,000 from Teva, which represented the reversal of a portion of the
refundable deposit for its exercise of the exclusivity option for certain
products.
The balance of $1,515,000 of other revenue represents revenues recognized
pursuant to strategic agreements with Schering-Plough, Wyeth, Novartis and
Leiner. These amounts represent the amortization of the milestone payments
received by the Company, over the life of the agreement. The following table
summarizes the activity in net revenues for the nine months ended September 30,
2004 and 2003:
20
Nine Months Ended
September 30,
-------------------------
(in $000's) 2004 2003
-------- -------
Product sales $109,978 $53,713
Less:
Rebates (4,441) (4,857)
Chargebacks (7,207) (6,000)
Product return reserve (3,844) (709)
Other credits (2,688) (1,713)
-------- -------
Net sales 91,798 40,434
Revenue from reversal of refundable deposit from Teva 2,500 --
Other Revenues 1,515 1,555
-------- -------
Total Revenues $ 95,813 $41,989
======== =======
For chargebacks and rebates, refer to Note 4; for product returns reserve, refer
to Note 8.
The rebates, chargebacks, returns and other credits decreased for the nine
months ended September 30, 2004 to approximately 17% of product sales as
compared to approximately 25% for the comparable period in 2003. This decrease
was mainly due to sales of Bupropion Hydrochloride) 100 mg and 150 mg Controlled
Release Tablets, and Loratadine and Pseudoephedrine Sulfate (5mg/120mg) 12-hour
Extended Release Tablets, and Orally Disintegrating Tablets. The Loratadine and
Pseudoephedrine Sulfate (5mg/120mg) 12-hour Controlled Extended Release Tablets
and Orally Disintegrating Tablets are exempt from rebates, chargebacks and other
credits pursuant to the agreements with Schering-Plough, Wyeth, Novartis, and
Leiner. The product sales reported by Teva to IMPAX are net of rebates,
chargebacks and other credits pursuant to the June 2001 Strategic Alliance
Agreement. We began estimating returns for products marketed by our Rx Partners,
such as Teva, based on our internal returns analysis and historical industry
statistics. The reserve for sales returns for products marketed by Rx Partners
was $1,244,000 at September 30, 2004.
The following table summarizes the net sales for the nine months ended September
30, 2004 as compared to the nine months ended September 30, 2003 by marketing
channel:
Nine Months Ended
September 30,
-------------------------
(in $000's) 2004 2003
-------- -------
Global $ 40,451 $27,049
Rx Partners 38,708 --
OTC 12,639 13,385
-------- -------
Total Net Sales $ 91,798 $40,434
======== =======
The increase in Global products of approximately $13.4 million in the first nine
months of 2004 as compared to the same period in 2003 was primarily due to new
products introduced in 2004 and late 2003, such as Demeclocycline with net sales
of approximately $7.7 million, Flavoxate with net sales of approximately $2.1
million, Carbidopa/Levodopa with net sales of approximately $2.9 million, and
higher sales of previously introduced product, Orphenadrine with net sales of
approximately $1.8 million, and partially offset by lower sales of
Fludrocortisone of approximately $1.6 million.
The Rx Partners year-over-year increase for the nine months ended September 30,
2004 was primarily due to shipments of our generic versions of Wellbutrin(R) SR
(Bupropion Hydrochloride) 100 mg and 150 mg Controlled Release Tablets, which
commenced shipment in the first quarter of 2004, and Zyban(R) (Bupropion
Hydrochloride) 150 mg Extended Release Tablets, which commenced shipment during
the second quarter of 2004. The OTC products sales decreased by approximately
$746,000 from the same period in the prior year due, primarily, to the timing of
the initial launch in 2003.
Rollforward analyses for each significant revenue dilution item are listed on
Note 4 and Note 8.
COST OF SALES
The cost of sales for the nine months ended September 30, 2004, was $54,679,000
as compared to $30,444,000 for the same period in 2003. The overall increase in
cost of sales was primarily due to the increase in cost of materials as a result
of increased product sales and approximately $1.9 million of various production
batches written-off, of which $135,000 was for new products. This includes
approximately $34,000 for Omeprazole capsules and approximately $101,000 for
Loratadine and Pseudoephedrine D-24, which were part of the validation
manufacturing transition effort. The estimated plant capacity utilization during
the nine months ended September 30, 2004 approximated 71% of total capacity
available and we expect to have excess capacity in the fourth quarter of 2004.
The full plant capacity utilization in 2005 is highly dependent on new product
approvals. At this time, we cannot project the effect of potential excess
capacity on future operations and liquidity.
21
GROSS MARGIN
Gross margin for the nine months ended September 30, 2004 was $41,134,000 or
approximately 43% of total revenues, as compared to $11,545,000 or approximately
27% of total revenues, for the same period in 2003. The year-over-year increase
in the gross margin percentage was primarily due to the introduction of new
products since last year with higher margins, such as Bupropion Hydrochloride,
Demeclocycline Hydrochloride, Flavoxate, and Carbidopa/Levodopa, and the
$2,500,000 revenue from Teva related to the refundable deposit.
RESEARCH AND DEVELOPMENT EXPENSES
The research and development expenses for the nine months ended September 30,
2004 were $15,266,000 less reimbursements of $306,000 by Teva under the
Strategic Alliance Agreement signed in June 2001, as compared to $10,463,000
less reimbursements of $247,000 for the same period in 2003. The higher research
and development expenditures in 2004 as compared to 2003 were primarily
attributable to clinical studies of approximately $1,464,000, higher personnel
costs of approximately $1,447,000, API of approximately $810,000, biostudies of
approximately $164,000, outside development costs of approximately $253,000, and
supplies of approximately $177,000.
PATENT LITIGATION EXPENSES
The patent litigation expenses for the nine months ended September 30, 2004 were
$7,146,000 as compared to $1,842,000 for the same period in 2003. The
year-to-year increase for the nine months was primarily due to the ongoing
Paragraph IV litigation related to our ANDAs for Omeprazole Capsules,
Fenofibrate Tablets, Fexofenadine and Pseudoephedrine Tablets, Oxybutynin
Tablets and generic Adderall Capsules. The 2003 expense was partially offset by
AIG patent litigation insurance payments.
SELLING EXPENSES
The selling expenses for the nine months ended September 30, 2004 were
$2,345,000 as compared to $1,552,000 for the same period in 2003. The increase
in selling expenses as compared to 2003 was primarily due to new leased office
expenses of $219,000, higher personnel costs of approximately $218,000, freight
costs of approximately $88,000, market research of approximately $65,000, and
selling sheets of approximately $36,000.
GENERAL AND ADMINISTRATIVE EXPENSES
The general and administrative expenses for the nine months ended September 30,
2004 were $9,757,000 as compared to $6,526,000 for the same period in 2003. The
increase in general and administrative expenses as compared to 2003 was
primarily due to personnel costs of approximately $1,222,000, insurance premiums
of approximately $1,177,000, higher recruiting expenses of approximately
$234,000, supplies of approximately $129,000 and professional fees of
approximately $127,000.
INTEREST INCOME
Interest income for the nine months ended September 30, 2004 was $714,000 as
compared to $199,000 for the same period in 2003, primarily due to higher
average cash equivalents and short-term investments generated from the net
proceeds of the Company's offering of $95 million convertible senior
subordinated debentures issued in April 2004.
INTEREST EXPENSE
Interest expense for the nine months ended September 30, 2004 was $1,383,000 as
compared to $738,000 for the same period in 2003. The increase in interest
expense for 2004 was primarily due to the 1.25% interest accrued on the
Company's $95 million convertible senior subordinated debentures.
INCOME TAXES
On a quarterly basis, the Company evaluates its projected full year taxable
income and related book-to-tax timing difference and the use of NOL
carryforwards. The Company estimates that it is not subject to current year
income taxes. We evaluate the realizability of deferred tax assets on an annual
and quarterly basis or if there is a significant change in circumstance that may
cause a change in our judgment about the realizability of our deferred tax
assets. As of September 30, 2004, the Company has operating loss carryforward
aggregating approximately $112 million expiring from 2009 through 2023.
22
NET INCOME
The net income for the nine months ended September 30, 2004 was $6,272,000 as
compared to a net loss of $9,105,000 for the same period in 2003, primarily due
to higher sales, partially offset by higher research and development, patent
litigation, selling, and general administrative expenses.
LIQUIDITY AND CAPITAL RESOURCES
As of September 30, 2004, we had $89,603,000 in cash, cash equivalents and
short-term investments. Only $200,000 of the account balances are insured by the
Federal Depository Insurance Company (FDIC). The balance of the Company's cash
equivalents and the short-term investments are held in U.S. Treasury securities
and high-grade commercial paper, which are not insured by the FDIC.
The net cash provided by financing activities for the nine months ended
September 30, 2004, was approximately $100,891,000 consisting primarily of the
$95,000,000 proceeds, less capitalized costs of $3,612,000, from the Company's
offering of convertible senior subordinated debentures offering completed in
April 2004, and proceeds of $3,869,000 from issuance of common stock upon the
exercise of options and warrants.
In April 2004, the Company terminated the loan agreements with Pennsylvania
Industrial Development Authority and Delaware River Port Authority and repaid
the remaining balances totaling approximately $992,000.
For the nine months ended September 30, 2004, significant uses of cash from
operating activities included, primarily, the increase in accounts receivable
balance of $9,845,000 and inventory buildup of $9,753,000, of which $2,848,000
is unapproved inventory awaiting FDA approval, and the decrease in accounts
payable and other liabilities of $5,580,000, partially offset by favorable cash
flow from operations, (excluding depreciation and amortization) of $10,151,000.
Our raw material purchase commitments as of September 30, 2004 were
approximately $11 million.
Our capital expenditures for the nine months ended September 30, 2004 were
$8,692,000 as compared to $3,063,000 for the same period in 2003, due primarily
to building improvements and purchases of machinery and scientific equipment.
The net cash used in investing activities included $44,821,000 for the purchase
of the short term investments in U.S. Treasury securities and high-grade
commercial paper.
In December 2003, the Company transferred the $25 million Loan and Security
Agreement from Congress Financial Corporation to Wachovia Bank, N.A., thereby
securing lower interest and less restrictive borrowing terms. The interest rates
for the revolving loans are prime rate plus 0.75%, or eurodollar rate plus
2.75%, at our option, based on excess availability. The term loan has an
interest rate of prime rate plus 1.5%, or eurodollar rate plus 4%, at our
option. As of September 30, 2004, we borrowed approximately $5,000,000 against
the revolving credit line and $2,675,000 against the term loan. In April 2004,
the $25 million loan and security agreement was amended, as follows: (1) the
cash collateral requirement of $10 million was removed; (2) the adjusted excess
availability covenant was removed; (3) the maximum permitted capital expenditure
amount was aggregated to $45,000,000 for the years 2004 and 2005, and (4) as a
condition of items (1) and (2) above, IMPAX is required to maintain a minimum
cash balance at Wachovia of $25,000,000.
We have no interest rate or derivative financial instruments nor material
foreign exchange risks. We are also not party to any off-balance-sheet
arrangements, other than operating leases.
We expect to incur significant operating expenses, particularly research and
development and patent litigation, for the foreseeable future in order to
execute our business plan. We, therefore, anticipate that such operating
expenses, as well as planned capital expenditures for the next twelve months
ranging from $15 to $20 million, primarily in plant capacity expansion, will
constitute a material use of our cash resources.
To date, we have primarily funded our research and development and other
operating activities through equity and debt financing, and strategic alliances.
We have not paid any cash dividends on our common stock and we do not plan to
pay any such cash dividends in the foreseeable future. We plan to retain any
earnings for the operation and expansion of our business. Our loan agreements
prohibit the payment of dividends without the lender's consent.
23
RECENT ACCOUNTING PRONOUNCEMENTS
In January 2003, the FASB issued FASB Interpretation No. 46 (FIN 46),
"Consolidation of Variable Interest Entities." FIN 46 clarifies the application
of Accounting Research Bulletin No. 51, "Consolidated Financial Statements," to
certain entities in which equity investors do not have the characteristics of a
controlling financial interest or do not have sufficient equity at risk for the
entity to finance its activities without additional subordinated financial
support from other parties. FIN 46 applies immediately to variable interest
entities created after January 31, 2003, and to variable interest entities in
which an enterprise obtains an interest after that date. It applies in the first
fiscal year or interim period beginning after June 15, 2003, to variable
interest entities in which an enterprise holds a variable interest that it
acquired before February 1, 2003. FIN 46 applies to public enterprises as of the
beginning of the applicable interim or annual period. On October 8, 2003, the
FASB decided to defer FIN 46 until the first reporting period ending after
December 15, 2003. The provisions of this Interpretation did not have a material
impact on the Company's financial condition or results of operations.
In December 2003, the FASB issued FIN No. 46(R), "Consolidation of Variable
Interest Entities," clarifying the application of Accounting Research Bulletin
No. 51, "Consolidated Financial Statements," to certain entities in which equity
investors do not have the characteristics of a controlling financial interest or
do not have sufficient equity at risk for the entity to finance its activities
without additional subordinated financial support. The provisions of this
Interpretation did not have a material impact on the Company's financial
condition or results of operations.
In December 2003, the FASB revised SFAS 132, "Employers' Disclosure About
Pensions and Other Post Retirement Benefits." This Statement does not change the
measurement or recognition of those plans required by FASB No. 87, "Employers'
Accounting for Pensions," and No. 106, "Employers' Accounting for Post
Retirement Benefits Other than Pensions." This Statement retains the disclosure
requirements contained in FASB No. 132, "Employers' Disclosure about Pensions
and Other Post Retirement Plans." The provisions of this Statement did not have
a material impact on the Company's financial condition or results of operations.
During the nine months ended September 30, 2004 and 2003, the Company's
contributions to the 401-K Plan were $335,158 and $213,854, respectively.
In February 2004, the FASB issued revised FSPs pertaining to FIN 46(R). The
revised FSPs replace certain previously issued FIN 46 FSP for entities to which
FIN 46(R) is applicable. This revision to FIN 46 did not have a material impact
on the Company's financial condition or results of operation.
In February 2004, the FASB revised SFAS 133, "Accounting for Derivative
Instruments and Hedging Activities for Implementation Issue E2L, A1J, and C6."
The revisions to SFAS 133 did not have a material impact on the Company's
financial condition or results of operation.
In September 2004, the FASB discussed EITF 04-08, "The Effect of Contingently
Convertible Debt on Diluted Earnings Per Share." The EITF task force has
proposed that companies count the shares that could be issued upon conversion of
securities like the Company's debentures when calculating fully diluted per
share earnings. This EITF is not yet effective. However, we disclosed in Note 2
of our Condensed Financial Statements the potential effect of this EITF on the
Company's fully diluted EPS calculation.
MAJOR OPERATIONAL HIGHLIGHTS FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2004
o On January 28, 2004, IMPAX announced that the FDA granted final approval to
the Company's ANDA for its generic version of Wellbutrin(R) SR (Bupropion
Hydrochloride) 100 mg Controlled Release Tablets and granted tentative
approval to the Company's generic version of Wellbutrin SR 150 mg
Controlled Release Tablets. GlaxoSmithKline markets Wellbutrin SR for the
treatment of depression. According to NDCHealth, U.S. sales of these dosage
forms of Wellbutrin SR Tablets and their generic equivalents were
approximately $1.1 billion in the twelve months ended August 31, 2004.
o On January 29, 2004, IMPAX announced that the Court of Appeals for the
Federal Circuit in Washington, D.C. upheld a lower court decision that
ruled against certain claims by GlaxoSmithKline in regards to the Company's
ANDA for Wellbutrin SR (Bupropion Hydrochloride) 100 mg and 150 mg and for
Zyban(R) (Bupropion Hydrochloride) 150 mg. GlaxoSmithKline markets
Wellbutrin SR for the treatment of depression and Zyban for smoking
cessation.
o On February 27, 2004, IMPAX announced that the FDA granted tentative
approval to the Company's ANDA for its generic version of Allegra(R)-D
(Fexofenadine Hydrochloride and Pseudoephedrine Hydrochloride 60mg/120mg)
Extended Release Tablets. Aventis Pharmaceuticals markets Allegra-D for the
treatment of the symptoms associated with seasonal allergic rhinitis.
According to NDCHealth, U.S. sales of Allegra-D were approximately $433
million in the twelve months ended August 31, 2004.
24
o On March 5, 2004, IMPAX announced that the FDA granted final approval to
the Company's ANDA for a generic version of Claritin(R)-D 24-Hour
(Loratadine and Pseudoephedrine Sulfate, 10mg/240mg) Extended Release
Tablets. Schering-Plough Corporation markets Claritin-D 24-Hour as an
over-the-counter (OTC) drug for the relief of symptoms of seasonal allergic
rhinitis (hay fever). According to NDCHealth, U.S. sales of Claritin-D
24-Hour and its generic equivalent were $5.6 million for the twelve months
ended August 31, 2004.
o On March 8, 2004, IMPAX announced that the FDA granted tentative approval
to the Company's ANDA for its generic version of Tricor(R) (Fenofibrate)
Tablets. Tricor Tablets are marketed by Abbott Laboratories, Inc. to assist
patients in managing their cholesterol levels. The drug is indicated for
use in reducing elevated LDL cholesterol, total cholesterol, triglycerides
and Apo B and increasing HDL cholesterol in patients with primary
hypercholesterolemia or mixed lipidemia. The drug has also been approved as
adjunctive therapy for the treatment of hypertriglyceridemia, a disorder
characterized by elevated levels of very low density lipoprotein (VLDL) in
the plasma. According to NDCHealth, U.S. sales of Tricor Tablets were
approximately $716 million for the twelve months ended August 31, 2004.
o On March 22, 2004, IMPAX announced that the FDA granted final marketing
approval to the Company's ANDA for its generic version of Wellbutrin SR
(Bupropion Hydrochloride) 150 mg Controlled Release Tablets. The FDA had
previously granted final approval for the Company's application for the 100
mg strength. GlaxoSmithKline markets Wellbutrin SR for the treatment of
depression. Both products were shipped to our marketing partner, Teva.
o On March 23, 2004, IMPAX announced that the FDA granted final marketing
approval to the Company's ANDA for its generic version of Declomycin(R)
(Demeclocycline Hydrochloride) 150 and 300 mg. Tablets. ESP Pharma markets
Declomycin for the treatment of various infections. According to NDCHealth,
U.S. sales of Declomycin and its generic equivalent were approximately $32
million for the twelve months ended August 31, 2004.
o On May 17, 2004, IMPAX announced that the FDA granted final approval to the
Company's ANDA for Carbidopa/Levodopa Extended Release Tablets, its generic
version of Sinemet(R) CR tablets. Bristol-Myers Squibb markets Merck &
Co.'s Sinemet CR exclusively in the U.S. for the treatment of Parkinsonism.
According to NDCHealth, U.S. prescription sales of Sinemet CR and its
generic equivalents were $121 million in the twelve months ended August 31,
2004.
o On May 27, 2004, IMPAX announced that the FDA granted final marketing
approval to the Company's ANDA for its generic version of Zyban (Bupropion
Hydrochloride) 150 mg Controlled Release Tablets. GlaxoSmithKline markets
Zyban for smoking cessation. According to NDCHealth, U.S. sales of Zyban
and its generic equivalents were approximately $55 million in the twelve
months ended August 31, 2004.
o On May 28, 2004, IMPAX announced that the FDA granted final marketing
approval to the Company's ANDA for its generic version of Proamatine(R),
Midodrine Hydrochloride 2.5 and 5 mg Tablets. Shire Pharmaceuticals Group
plc markets Proamatine for treatment of symptomatic orthostatic
hypotension. According to NDCHealth, U.S. market sales of Proamatine 2.5 mg
and 5 mg and their generic equivalents and the two other marketed generic
versions were approximately $46 million in the twelve months ended August
31, 2004.
o On June 18, 2004, IMPAX announced that the FDA granted IMPAX a second tier
180-day exclusivity related to its pending ANDA for a generic version of
Glucophage XR(R), Metformin HCl Extended Release Tablets, 500mg. IMPAX has
selectively waived its rights to this exclusivity to Teva Pharmaceuticals
USA Inc. and will be sharing in the profits of Teva's Metformin HCl
Extended Release Tablets as provided for in the Strategic Alliance
Agreement between IMPAX and Teva signed in June 2001. On August 2, 2004,
the FDA granted final marketing approval to the Company's ANDA for its
generic version of Glucophage XR, Metformin HCl Extended Release Tablets,
500 mg. Bristol-Myers Squibb markets Glucophage XR for the improvement of
glycemic control in patients with type 2 diabetes. According to NDCHealth,
U.S. market sales of Glucophage XR 500 mg and other marketed generic
versions were approximately $348 million in the twelve months ended August
31, 2004.
o On July 12, 2004, IMPAX announced that it has signed a series of agreements
with Leiner Health Products, LLC for the supply and distribution of the
Company's Loratadine Orally Disintegrating Tablets (ODT) and Loratadine and
Pseudoephedrine Sulfate Extended Release Tablets 24 hour products. Both of
these products are indicated for the relief of symptoms of seasonal
allergic rhinitis (hay fever). These products will be manufactured by IMPAX
and marketed by Leiner as over the counter (OTC) store brand equivalents to
both Claritin(R) Reditabs(R) and Claritin-D(R) 24-hour respectively.
o On August 2, 2004, IMPAX announced that the FDA has granted final marketing
approval to the Company's Abbreviated New Drug Application for its generic
version of Glucophage XR(R), Metformin HCl Extended Release Tablets, 500mg.
Bristol-Myers Squibb markets Glucophage XR(R) for the improvement of
glycemic control in patients with type 2 diabetes.
25
o On September 8, 2004, IMPAX announced that its Omeprazole Delayed Release
Capsules 20mg have been commercially launched by Teva Pharmaceutical
Industries Ltd. Omeprazole Delayed Release Capsules are a generic version
of Prilosec(R) marketed by AstraZeneca for the treatment of
duodenal/gastric ulcers and GERD (gastro-esophageal reflux disease).
According to NDC Health, U.S. sales of Prilosec 20mg and its generic
equivalents were $1.1 billion for the twelve months ending August 31, 2004.
o On September 28, 2004, IMPAX announced that the FDA has granted final
approval to the Company's Abbreviated New Drug Application for a generic
version of OxyContin(R) (Oxycodone Hydrochloride) Controlled Release 80mg
Tablets. Purdue Pharma markets OxyContin for the management of moderate to
severe pain. According to NDCHealth, U.S. sales of OxyContin Controlled
Release 80mg Tablets and its generic equivalent were $685 million for the
twelve months ended August 31, 2004.
ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
The Company's cash and cash equivalents includes U.S. government and short-term
high-grade commercial paper stated at cost which approximates market value. The
primary objective of the Company's investment activities is to preserve
principal and maximize yields without significantly increasing risk. To achieve
this objective, the Company maintains its portfolio in a variety of high credit
quality securities, including U.S. Government securities, treasury bills, and
short-term high-grade commercial paper. All of the Company's portfolio matures
in less than one year. The carrying value of the portfolio approximates the
market value at September 30, 2004. The Company's debt instruments at September
30, 2004 are subject to fixed and variable interest rates and principal
payments. We believe that the fair value of our fixed and variable rate
long-term debt approximates their carrying value of approximately $108 million
at September 30, 2004. While changes in market interest rates may affect the
fair value of our fixed and variable rate long-term debt, we believe the effect,
if any, of reasonably possible near-term changes in the fair value of such debt
on the Company's financial statements will not be material.
We have no interest rate or derivative financial instruments nor material
foreign exchange risks. We are also not party to any off-balance-sheet
arrangements, other than operating leases.
ITEM 4. CONTROLS AND PROCEDURES
The Company, under the supervision and with the participation of our management,
including our principal executive officer and our principal financial officer,
evaluated the effectiveness of our disclosure controls and procedures (as
defined in Exchange Act Rule 13a-15(e)), as of the end of the period covered by
this report. Based on this evaluation, including consideration of the
restatement discussed below, our principal executive officer and our principal
financial officer concluded that our disclosure controls and procedures are
effective in reaching a reasonable level of assurance that information required
to be disclosed by us in the reports that we file or submit under the Securities
Exchange Act of 1934, as amended, is recorded, processed, summarized, and
reported within the time period specified in the Securities and Exchange
Commission's rules and forms.
The principal executive officer and principal financial officer also conducted
an evaluation of internal control over financial reporting ("Internal Control")
to determine whether any changes in Internal Controls occurred during the
quarter that have materially affected, or which are reasonably likely to
materially affect, Internal Controls. Based on this evaluation, there has been
no such change during the quarter covered by this report.
A control system, no matter how well conceived and operated, can provide only
reasonable, not absolute, assurance that the objectives of the control system
are met. Further, the design of a control system must reflect the fact that
there are resource constraints, and the benefits of controls must be considered
relative to their costs. Because of the inherent limitations in all control
systems, no evaluation of controls can provide absolute assurance that all
control issues and instances of fraud, if any, within the Company have been
detected. The Company conducts periodic evaluations of its internal controls to
enhance, where necessary, its procedures and controls. Because of the inherent
limitations in a cost-effective control system, misstatements due to error or
fraud may occur and not be detected.
Subsequent to issuance of the condensed financial statements for the quarter
ended June 30, 2004, the Company restated its condensed financial statements as
described in Note 11. The Company determined that a material weakness existed in
its internal controls. The Company is endeavoring to take steps to correct the
deficiency that gave rise to this restatement. These steps include, but are
not limited to, regular discussions with Teva management regarding their monthly
financial reports to IMPAX on our products marketed by Teva via monthly
teleconferences and quarterly meetings. These discussions will cover all the
areas of revenue recognition for these products, including but not limited to,
sales credits, product returns and internal controls over Teva's financial
reporting to IMPAX. Our procedures will include a review of applicable
documentation for IMPAX revenue sharing. The Audit Committee of the Company's
Board of Directors may take additional steps as deemed necessary. The company is
endeavoring to take steps under the Strategic Alliance Agreement to ensure that
all such adjustments granted by its strategic partner in the future are
reported to the Company on a timely basis. Under the contract terms, the Company
has the option to perform an annual audit with our strategic partner. The
Company has disclosed and discussed this with its Audit Committee.
For more information concerning the restatement, see Note 11 in the Notes to
Financial Statements contained in the Company's Quarterly Report on Form 10-Q/A
for the quarter ended March 31, 2004 and Note 14 in the Notes to Financial
Statements contained in the Company's Quarterly Report on Form 10-Q/A for the
quarter ended June 30, 2004.
26
PART II - OTHER INFORMATION
----------------------------
ITEM 1. LEGAL PROCEEDINGS
PATENT LITIGATION
There has been substantial litigation in the pharmaceutical, biological, and
biotechnology industries with respect to the manufacture, use, and sale of new
products that are the subject of conflicting patent rights. One or more patents
cover most of the brand name controlled-release products for which we are
developing generic versions. Under the Hatch-Waxman Amendments, when a drug
developer files an ANDA for a generic drug, and the developer believes that an
unexpired patent which has been listed with the FDA as covering that brand name
product will not be infringed by the developer's product or is invalid or
unenforceable, the developer must so certify to the FDA. That certification must
also be provided to the patent holder, who may challenge the developer's
certification of non-infringement, invalidity or unenforceability by filing a
suit for patent infringement within 45 days of the patent holder's receipt of
such certification. If the patent holder files suit, the FDA can review and
approve the ANDA, but is prevented from granting final marketing approval of the
product until a final judgment in the action has been rendered, or 30 months
from the date the certification was received, whichever is sooner. Should a
patent holder commence a lawsuit with respect to an alleged patent infringement
by us, the uncertainties inherent in patent litigation make the outcome of such
litigation difficult to predict. The delay in obtaining FDA approval to market
our product candidates as a result of litigation, as well as the expense of such
litigation, whether or not we are successful, could have a material adverse
effect on our results of operations and financial position. In addition, there
can be no assurance that any patent litigation will be resolved prior to the
30-month period. As a result, even if the FDA were to approve a product upon
expiration of the 30-month period, we may not commence marketing that product if
patent litigation is still pending.
Lawsuits have been filed against us in connection with fourteen of our Paragraph
IV filings. The outcome of such litigation is difficult to predict because of
the uncertainties inherent in patent litigation.
ASTRAZENECA AB ET AL. V. IMPAX: THE OMEPRAZOLE CASES
-------------------------------
In May 2000, AstraZeneca AB and four of its related companies filed suit against
IMPAX in the U.S. District Court in Wilmington, Delaware claiming that IMPAX's
submission of an ANDA for Omeprazole Delayed Release Capsules, 10 mg and 20 mg,
constitutes infringement of six U.S. patents relating to AstraZeneca's
Prilosec(R) product. The action seeks an order enjoining IMPAX from marketing
Omeprazole Delayed Release Capsules, 10 mg and 20 mg until February 4, 2014, and
reimbursement for costs and attorney fees associated with this litigation.
In February 2001, AstraZeneca and the same related companies filed the same suit
against IMPAX in the same federal court in Delaware for infringement, based upon
IMPAX's amendment to its ANDA adding 40 mg strength Omeprazole Delayed Release
Capsules.
AstraZeneca filed similar lawsuits against nine other generic pharmaceutical
companies (Andrx, Genpharm, Cheminor, Kremers, LEK, Eon, Mylan, Apotex, and
Zenith). Due to the number of these cases, a multidistrict litigation
proceeding, In re Omeprazole 10 mg, 20 mg, and 40 mg Delayed Released Capsules
Patent Litigation, MDL-1291, has been established to coordinate pre-trial
proceedings. Both lawsuits filed by AstraZeneca against IMPAX have been
transferred to the multidistrict litigation jurisdiction.
Early in the multidistrict litigation, the trial court ruled that one of the six
patents-in-suit was not infringed by the sale of a generic omeprazole product
and that certain other patents were invalid. These rulings effectively
eliminated four patents from the trial of these infringement cases, although
AstraZeneca may appeal these rulings as part of the overall appeal process in
the case.
On October 11, 2002, after a trial involving Andrx, Genpharm, Cheminor, and
Kremers, the trial judge handling the multidistrict litigation ruled on
AstraZeneca's complaints that three of these four defendants ("First Wave
Defendants") infringed the remaining patents-in-suit. The trial judge ruled that
three of the First Wave defendants, Andrx, Genpharm, and Cheminor, infringed the
remaining two patents asserted by AstraZeneca in its complaints, and that those
patents are valid until 2007. In the same ruling, the trial court ruled that the
remaining First Wave Defendant, Kremers, did not infringe either of the
remaining two patents. Kremers' formulation was held to differ from the
formulation used by the other First Wave Defendants in several respects. In
mid-December 2003, the U.S. Court of Appeals for the Federal Circuit affirmed
the October 2002 ruling in all respects. Subsequent petitions for rehearing have
been denied.
27
The formulation that IMPAX employs in manufacturing its generic equivalent of
omeprazole has not been publicly announced. IMPAX's formulation has elements
that resemble those of other First Wave Defendants in certain respects, but it
also has elements that differ. Although the ruling by the trial court in the
multidistrict litigation has a significant effect on the course of AstraZeneca's
litigation against IMPAX, application of the trial court's opinion as to IMPAX
is not certain. IMPAX believes that it has defenses to AstraZeneca's claims of
infringement, but the opinion rendered by the trial court in the First Wave
cases makes the outcome of AstraZeneca's litigation against IMPAX uncertain.
Two of the remaining six defendants ("Second Wave Defendants") filed Motions for
Summary Judgment of Non-Infringement, based upon the October 2002 ruling. The
trial court has deferred ruling on those motions until discovery is completed.
In August 2003, the court issued an order dismissing four of the
patents-in-suit, three with prejudice. On September 30, 2003, as a result of the
court's dismissal, AstraZeneca served each of the Second Wave Defendants,
including IMPAX, with an amended complaint. In October 2003, IMPAX filed an
answer to the amended complaint in which we asserted a new counterclaim with
antitrust allegations. The counterclaim will be severed, and proceedings
relating to it will be stayed until after trial of the patent infringement case.
In December 2003, the trial court entered a new scheduling order governing
pre-trial proceedings relating to the Second Wave Defendants, including IMPAX.
The schedule for completion of the litigation in the Second Wave, including
AstraZeneca's litigation against IMPAX, now provides that all fact discovery
(with certain exceptions) is complete. AstraZeneca's expert reports on issues as
to which it bears the burden of proof, including issues of alleged infringement,
were served on February 17, 2004. IMPAX's responsive expert reports were served
on July 12, 2004. Astra's reply reports were served in early September 2004,
prior to the launch of IMPAX's commercial product.
The December 2003 scheduling order was amended most recently in August 2004.
Pursuant to the terms of the amended scheduling order, expert depositions have
commenced and are scheduled to conclude in January 2005. The amended scheduling
order also allows for the filing of summary judgment motions beginning in March
2005. The parties may also request leave of the Court to file summary judgment
motions earlier than the March 2005 date. The amended scheduling order states
that no further extensions of time shall be granted to the parties.
IMPAX may file motions for summary judgment at the appropriate juncture in this
case. It is likely that one or more additional parties to this matter may also
file motions for summary judgment. If the case is not resolved through such
motions, the court will schedule a date for trial. At this time, we believe it
is likely that, given the proceedings in the First Wave cases, the case against
IMPAX will be transferred back to New York for a consolidated trial before the
same judge who decided the First Wave cases. IMPAX currently believes, however,
that any trial that might be scheduled in the case will commence in 2005.
As noted in Item 2 (Major Operational Highlights), in conjunction with its
strategic partner, Teva, IMPAX recently has initiated a commercial launch of
certain omeprazole products which were the subject of its ANDA application and
which are at issue in this litigation. If IMPAX is not ultimately successful in
establishing invalidity or non-infringement, the court may award monetary
damages associated with the commercial sale of IMPAX's omeprazole products.
Pursuant to the Strategic Alliance Agreement with Teva, however, Teva is
responsible for indemnifying the Company with respect to any such monetary
damages, provided certain conditions are met.
In September 2004, in accordance with the terms of the Strategic Alliance
Agreement between IMPAX and Teva Pharmaceuticals, Teva exercised its option to
designate counsel to handle the omeprazole litigation, and IMPAX's counsel in
the matter were replaced. New counsel entered their appearances in the
litigation on behalf of IMPAX in July 2004. In October 2004, Astra filed
pleadings with the Court setting forth causes of action against Teva, and
amending its claims against IMPAX to clearly state claims alleging willful
infringement of the patents in suit, and seeking monetary damages for alleged
infringement. It is expected that the Court will grant Astra's request to add
Teva as a party and to amend its claims against IMPAX. Under the Strategic
Alliance Agreement, Teva has the obligation to indemnify IMPAX for certain
losses, and to pay a large share of the attorneys fees that will be incurred
after Teva's exercise of its option under the Strategic Alliance Agreement. It
is uncertain whether, if at all, the addition of Teva and the amendment of
Astra's claims against IMPAX will delay the ultimate resolution of Astra's
claims against IMPAX. IMPAX intends to vigorously defend the action brought by
AstraZeneca, and it expects that counsel selected by Teva will vigorously
represent the interests of both IMPAX and Teva in the litigation.
28
AVENTIS PHARMACEUTICALS INC., ET AL. V. IMPAX: THE FEXOFENADINE CASES
On March 25, 2002, Aventis Pharmaceuticals Inc., Merrell Pharmaceuticals Inc.,
and Carderm Capital L.P. (collectively referred to as Aventis) sued IMPAX in the
U.S. District Court for the District of New Jersey (Civil Action No. 02-CV-1322)
alleging that IMPAX's proposed fexofenadine and pseudoephedrine hydrochloride
tablets, containing 60 mg of fexofenadine and 120 mg of pseudoephedrine
hydrochloride, infringe U.S. Patent Nos. 6,039,974; 6,037,353; 5,738,872;
6,187,791; 5,855,912; and 6,113,942. On November 7, 2002, Aventis filed an
amended complaint, which added an allegation that IMPAX's Fexofenadine and
Pseudoephedrine Hydrochloride 60 mg/120 mg Extended Release Tablet product
infringes U.S. Patent No. 6,399,632. Aventis seeks an injunction preventing
IMPAX from marketing its Fexofenadine and Pseudoephedrine Hydrochloride 60
mg/120 mg Extended Release Tablet product until the patents-in-suit have
expired, and an award of damages for any commercial manufacture, use, or sale of
IMPAX's Fexofenadine and Pseudoephedrine Hydrochloride 60 mg/120 mg Extended
Release Tablet product, together with costs and attorneys' fees.
Fact discovery in this action is scheduled to close in January 2005. IMPAX
believes that it has defenses to the claims made by Aventis based on
noninfringement and invalidity. A tentative trial date has been scheduled for
October 2005.
Aventis has also filed a suit against Barr Laboratories, Inc., Mylan
Pharmaceuticals, Inc., Dr. Reddy's Pharmaceuticals and Teva Pharmaceuticals USA,
Inc. in New Jersey asserting the same patent infringement against these
defendants' proposed Fexofenadine and Pseudoephedrine or Fexofenadine products.
The IMPAX case has been consolidated for trial with the Barr, Mylan, Dr. Reddy
and Teva cases.
On March 25, 2004, Aventis and AMR filed a complaint and first amended complaint
against IMPAX and Ranbaxy, alleging infringement of two additional patents
relating to the process for making the active pharmaceutical ingredient,
fexofenadine hydrochloride. These patents, United States Patent Nos. 5,581,011
and 5,750,703, are owned by AMR and exclusively licensed to Aventis.
On July 23, 2003, IMPAX filed Summary Judgment motions for non-infringement of
U.S. Patent Nos. 6,039,974, 6,113,942, and 5,855,912; and for non-infringement
and invalidity of U.S. Patent No. 5,738,872. Oral argument for the Summary
Judgment Motion regarding the `912, `942, and `974 patents was heard on November
3, 2003. Oral argument for the Summary Judgment Motion regarding the `872 patent
was heard on December 8, 2003. On June 29, 2004, the court granted the Company's
Motions for Summary Judgment of Non-infringement of the `912 and `942 patents
and denied the Company's Motion for Summary Judgment of Non-infringement of the
`974 patent. At the same time, the court ordered that a ruling on the Company's
motion for Summary Judgment for the Non-infringement and invalidity of the `872
patent is reserved pending a Markman hearing held on September 9, 2004 to assist
the court in construing the patent's product-by-process claims. On October 4,
2004, Judge Greenaway construed the claims of the fifth patent in favor of IMPAX
and the other defendants. Aventis is seeking reconsideration of that ruling by
the court. IMPAX will be able to assert both non-infringement and invalidity of
the remaining patents (if necessary) at trial.
PURDUE PHARMA L.P. ET AL. V IMPAX: THE OXYCODONE CASES
----------------------------------
On April 11, 2002, Purdue Pharma and related companies filed a complaint in the
U.S. District Court for the Southern District of New York alleging that IMPAX's
submission of ANDA No. 76-318 for 80 mg oxycodone tablets infringes three
patents owned by Purdue. The Purdue patents are U.S. Patent Nos. 5,508,042,
5,549,912 and 5,656,295; all directed to controlled release opioid formulations.
On September 19, 2002, Purdue filed a second Infringement Complaint regarding
IMPAX's 40 mg oxycodone generic product. On October 9, 2002, Purdue filed a
third Infringement Complaint regarding IMPAX's 10 mg and 20 mg oxycodone generic
products. IMPAX filed its answer and counterclaims in each case on October 3,
2003. On November 25, 2003, Purdue submitted their reply to our counterclaims.
Purdue is seeking, among other things, a court order preventing IMPAX from
manufacturing, using or selling any drug product that infringes the subject
Purdue patents.
Purdue previously sued Boehringer Ingelheim/Roxane, Endo and Teva on the same
patents. One or more of these defendants may resolve the invalidity issues
surrounding the Purdue patents prior to when IMPAX's case goes to trial. The
Boehringer Ingelheim/Roxane suit is stayed. The Endo action was tried in June
2003 and post trial briefs have been filed. In January 2004, the judge in the
Endo action ruled that the three patents in suit, the same patents that Purdue
has asserted against IMPAX, are unenforceable because they were inequitably
procured and enjoined their enforcement. Purdue has appealed that ruling to the
Court of Appeals for the Federal Circuit, and oral argument is scheduled for
November 3, 2004.
29
IMPAX V. AVENTIS PHARMACEUTICALS, INC.: THE RILUZOLE CASE
---------------------------------------
In June 2002, IMPAX filed suit against Aventis Pharmaceuticals, Inc. in the U.S.
District Court in Wilmington, Delaware, seeking a declaration that the filing of
an ANDA to engage in a commercial manufacture and/or sale of Riluzole 50 mg
Tablets for treatment of patients with amyotrophic lateral scleroses (ALS) does
not infringe claims of Aventis' U.S. Patent No. 5,527,814 (`814 patent) and a
declaration that this patent is invalid.
In response to IMPAX's complaint, Aventis filed counterclaims for direct
infringement and inducement of infringement of the `814 patent. In December
2002, the district court granted Aventis' Motion for Preliminary Injunction and
enjoined IMPAX from infringing, contributory infringing, or inducing any other
person to infringe Claims 1, 4 or 5 of the `814 patent by selling, offering for
sale, distributing, marketing or exporting from the United States any
pharmaceutical product or compound containing riluzole or salt thereof for the
treatment of ALS.
The trial was completed on October 30, 2003, and post-trial briefing was
completed in December 2003. On January 30, 2004, the court denied IMPAX's Motion
for Summary Judgment on inequitable conduct and, on February 5, 2004, the court
denied IMPAX's Motion for Summary Judgment on non-infringement of certain
claims. In September 2004, the court ruled the `814 patent is valid, enforceable
and infringed by IMPAX's proposed generic riluzole product. The Company is
considering its options regarding a possible appeal.
If IMPAX is not ultimately successful in proving invalidity or unenforceability,
there is a substantial likelihood that the court will enter a permanent
injunction enjoining IMPAX from marketing Riluzole 50 mg Tablets for the
treatment of ALS in the United States until the expiration of the `814 patent
(June 18, 2013). If IMPAX is ultimately successful in proving either defense,
the preliminary injunction would be set aside and IMPAX would be permitted to
market its Riluzole 50 mg Tablet product for the treatment of ALS in the United
States.
ABBOTT LABORATORIES V. IMPAX: THE FENOFIBRATE TABLET CASES
-----------------------------
In January 2003, Abbott Laboratories and Fournier Industrie et Sante and a
related company filed suit against IMPAX in the U.S. District Court in
Wilmington, Delaware claiming that IMPAX's submission of an ANDA for Fenofibrate
Tablets, 160 mg, constitutes infringement of two U.S. patents owned by Fournier
and exclusively licensed to Abbott, relating to Abbott's Tricor tablet product.
In March 2003, Abbott and Fournier filed a second action against IMPAX in the
same court making the same claims against IMPAX's 54 mg Fenofibrate Tablets.
These cases were consolidated in April 2003.
In September 2003, Abbott and Fournier filed a third action against IMPAX in the
U.S. District Court in Wilmington, Delaware, claiming that IMPAX's submission of
its ANDA for 54 mg and 160 mg Fenofibrate Tablets constitutes infringement of a
third patent recently issued to Fournier and exclusively licensed to Abbott.
This action was also consolidated with the two previously consolidated actions
in December 2003. In January 2004, Abbott and Fournier filed a fourth action
relating to IMPAX's 54 mg and 160 mg Fenofibrate Tablets based upon a claim of
infringement of a fourth patent. The asserted patents are U.S. Patent Nos.
6,652,881, 6,589,552, 6,277,405 and 6,074,670. All four cases were consolidated
in March 2004. Fact and expert discovery in the consolidated cases closes in
November 2004 and the trial is currently set for June 2005. IMPAX has responded
to all four complaints by asserting that its proposed generic Fenofibrate Tablet
products do not infringe the patents-in-suit and by asserting that the
patents-in-suit are invalid.
All four actions seek an injunction preventing IMPAX from marketing its
Fenofibrate Tablet products until the expiration of the patents (January 9,
2018) and an award of damages for any commercial manufacture, use, or sale of
IMPAX's Fenofibrate Tablet product, together with costs and attorney fees.
SOLVAY PHARMACEUTICALS V. IMPAX: THE CREON CASE
-------------------------------
On April 11, 2003, Solvay Pharmaceuticals, Inc., manufacturer of the Creon(R)
line pancreatic enzyme products, brought suit against IMPAX in the U.S. District
Court for the District of Minnesota claiming that IMPAX has engaged in false
advertising, unfair competition, and unfair trade practices under federal and
Minnesota law in connection with the Company's marketing and sale of its Lipram
products. The suit seeks actual and consequential damages, including treble
damages, attorneys' fees, injunctive relief and declaratory judgments that would
prohibit the substitution of Lipram for prescriptions of Creon. On June 6, 2003,
IMPAX filed a Motion for Dismissal of Plaintiff's Complaint, which sought to
dismiss each count of Solvay's complaint. On January 9, 2004, the U.S. District
Court issued a ruling on IMPAX's Motion for Dismissal, dismissing two of the
counts set forth in the Complaint, including the count which sought a
declaratory judgment that Lipram may not lawfully be substituted for
prescriptions of Creon. On January 26, 2004, IMPAX filed its Answer to the
Complaint and Counterclaim alleging that Solvay wrongfully interfered with
IMPAX's business relationships. On February 17, 2004, Solvay filed its Reply to
IMPAX's Counterclaim. On February 24, 2004, the Rule 16 Scheduling Conference
was held and, on February 25, 2004, the Court issued a Scheduling Order setting
the deadline for discovery on January 14, 2005, and a tentative trial date for
July 1, 2005. On September 9, 2004, the Court issued an Amended Scheduling Order
pursuant to a stipulation filed by the parties, moving the deadline for
discovery to March 14, 2005. Fact discovery is currently ongoing in this case.
IMPAX believes it has defenses to Solvay's allegations and intends to pursue
these defenses vigorously.
30
ALZA CORPORATION V. IMPAX: THE OXYBUTYNIN CASE
----------------------------------------------
On September 4, 2003, Alza Corporation ("Alza") filed a lawsuit against IMPAX in
the U.S. District Court for the Northern District of California alleging patent
infringement of one patent, U.S. Patent No. 6,124,355, related to IMPAX's filing
of an ANDA for a generic version of Ditropan XL (Oxybutynin Chloride) Tablets, 5
mg, 10 mg, and 15 mg. Alza seeks an injunction, a declaration of infringement,
attorney's fees and costs. On October 24, 2003, IMPAX filed its Answer to the
Complaint, which included defenses to the infringement claim, and counterclaimed
for patent non-infringement and invalidity. Discovery is on-going and trial is
currently set for November 2005.
On October 24, 2003, IMPAX filed a lawsuit against Alza in the U.S. District
Court for the Northern District of California seeking a declaratory judgment
that four Alza patents relating to IMPAX's filing of an ANDA for a generic
version of Ditropan XL(R) (Oxybutynin Chloride) Tablets, 5 mg, 10 mg, and 15 mg
are invalid and/or not infringed by the commercial manufacture, use, offer for
sale, sale, or importation of the IMPAX product. On November 17, 2003, Alza
moved to dismiss the Company's complaint for lack of subject matter jurisdiction
based on Alza's argument that there is no case or controversy between the
parties with respect to these four patents. On April 19, 2004, the Court denied
Alza's motion. On May 18, 2004, the Court ordered the entry of a stipulation of
dismissal based on a covenant not to sue issued by Alza to the Company with
respect to four Alza patents in the case.
SHIRE LABORATORIES INC. V IMPAX: THE GENERIC ADDERALL CASE
----------------------------------------------------------
On December 29, 2003, Shire Laboratories, Inc., a subsidiary of Shire
Pharmaceuticals Group, PLC, filed a lawsuit against IMPAX in the U.S. District
Court for the District of Delaware alleging patent infringement on U.S. Patent
Nos. 6,322,819 and 6,605,300 related to filing of an ANDA to market a generic
version of Adderall XR(R) 30 mg capsules. IMPAX filed its answer on January 20,
2004, denying infringement and contesting the validity of both patents. All
discovery is expected to be completed by March 2005. A tentative court date has
been scheduled for October 11, 2005.
OTHER LITIGATION
STATE OF CALIFORNIA V. IMPAX
----------------------------
On August 7, 2003, IMPAX received an Accusation from the Department of Justice,
Bureau of Narcotic Enforcement, State of California ("BNE"), alleging that IMPAX
failed to maintain adequate controls to safeguard precursors from theft or loss
regarding our pseudoephedrine product in January 2003. IMPAX contested the
allegations in the Accusation and entered into discussions with the State of
California, Department of Justice, to bring resolution to this matter. IMPAX has
implemented a number of remedial measures aimed at improving the security and
accountability of precursor substances used by IMPAX and regulated by the
California Department of Justice, Bureau of Narcotic Enforcement. In March 2004,
following a theft of pseudoephedrine from IMPAX's facilities, the BNE filed an
Amended Accusation, again alleging that IMPAX failed to maintain adequate
controls to safeguard precursors from theft or loss regarding our
pseudoephedrine product. In May 2004, a Notice of Hearing was received from BNE,
which set the hearing of this matter, should one be necessary, for October 18
and October 19, 2004.
On October 11, 2004 IMPAX entered into a Stipulation with the California Bureau
of Narcotic Enforcement ("BNE") regarding IMPAX's California Precursor Business
Permit #201, applicable to the IMPAX facility located at 31153 San Antonio
Street, Hayward, California. Pursuant to the Stipulation, Permit #201 is
provisionally suspended, with such suspension stayed, for a period of two (2)
years, in which IMPAX must comply with the terms and conditions of the
Stipulation. The Stipulation provides: "Upon successful completion of the terms
of the Stipulation for the period of time in which it is in effect, IMPAX's
permit will be fully restored without having been suspended."
The Stipulation resolves both the original Accusation and the Amended
Accusation.
IMPAX DERIVATIVE LAWSUITS
-------------------------
On September 24, 2004, Impax Laboratories, Inc. received a Complaint filed by a
shareholder of the Corporation in the Superior Court for Alameda County,
California, purporting to state a derivative claim on behalf of the Company, as
a nominal defendant. The Complaint, brought by Catherine Burke, derivatively on
behalf of nominal defendant Impax Laboratories, Inc., Case No. RG04176541,
asserts claims against Robert L. Burr, David S. Doll, Barry Edwards, Charles
Hsiao, Larry Hsu, Michael Markbreiter, and Cornel C. Spiegler, each of whom is
an officer or director, or both, of the Company. The Complaint alleges claims
against these individuals under California Corporations Code ss. 25402, and
under California's common law relating to the fiduciary duties of corporate
officers and directors, arising from the sale of common stock of the Company by
the named individuals in June 2004.
31
A second, virtually identical complaint, brought by Crayton D. Leavitt, as
trustee of the Leavitt Family Trust, derivatively on behalf of nominal defendant
Impax Laboratories, Inc., Case No. RG04176931, received by the Company on
September 28, 2004, was filed in the same forum by another shareholder of the
Corporation against the same individuals. The complaints seek treble damages,
imposition of a constructive trust on the individual defendants, attorneys fees
and costs, and other relief as the court determines.
The Board has appointed a special litigation committee of disinterested
directors to investigate the merits of the allegations in the complaints and to
engage special counsel to assist in such investigation. Each of the named
individuals has informed the Company that he denies the allegations made in
these complaints, and that he will vigorously defend the claims asserted against
him.
The Company responded to each of the complaints on October 20, 2004, by filing a
motion to dismiss (called a demurrer in California State courts) and a motion to
stay the actions for 120 days to allow the special litigation committee to
complete its investigation. After these motions were filed, the plaintiffs
offered to stipulate to a stay of 120 days, and such a stipulation was filed
with the Court on October 29, 2004. As part of the stipulation, the Company
withdrew its motion to dismiss. An order for a 120 day stay was also submitted,
but it has not yet been signed by the judge.
There are no allegations in the two complaints against the Company. The special
litigation committee will determine whether the Company itself should pursue the
claims alleged or move to dismiss them.
The Company is aware that two law firms issued press releases on Friday,
November 12, 2004, indicating that they filed class action lawsuits against the
Company in the United States District Court for the Northern District of
California. According to the press releases, the complaints allege that the
Company and certain of its officers and directors violated the Securities
Exchange Act of 1934 by causing the Company's shares to trade at artificially
inflated levels through the issuance of false and misleading financial
statements. The complaints appear to focus, in part, on the Company's
announcement on November 3, 2004 that it would restate its earnings for the
first and second quarters of 2004 as a result of a strategic partner's
unforeseen revision of revenues from sales of one of the company's drugs during
such quarters. The Company has not yet been served with copies of the
complaints.
Other than the legal proceedings described above, we are not aware of any other
material pending or threatened legal actions, private or governmental, against
us. However, as we file additional applications with the FDA that contain
Paragraph IV certifications and develop new products, it is likely we will
become involved in additional litigation related to those filings or products.
INSURANCE
As part of our patent litigation strategy, we had obtained two policies covering
up to $7 million of patent infringement liability insurance from American
International Specialty Line Company ("AISLIC"), an affiliate of AIG
International. This litigation insurance covered us against the costs associated
with patent infringement claims made against us relating to seven of the ANDAs
we filed under Paragraph IV of the Hatch-Waxman Amendments. Both policies had
reached their limits of liability and the Company has collected all monies from
AIG, as of September 30, 2004 IMPAX does not have any receivables from AIG.
While Teva has agreed to pay 45% to 50% of the attorneys' fees and costs (in
excess of the $7 million covered by our insurance policies for six products)
related to the twelve products covered by our strategic alliance agreement with
them, we will be responsible for the remaining expenses and costs for these
products, and all of the costs associated with patent litigation for our other
products and our future products.
We do not believe that this type of litigation insurance will be available to us
on acceptable terms for our other current or future ANDAs. In those cases, our
policy is to record such expenses as incurred.
Product liability claims by customers constitute a risk to all pharmaceutical
manufacturers. We currently carry $80 million of product liability insurance for
our own manufactured products. This insurance may not be adequate to cover any
product liability claims to which we may become subject.
32
ITEM 6. EXHIBITS
(a) Exhibits
10.67 - Exclusive License, Supply and Distribution Agreement Between Leiner Health
Products, LLC and Impax Laboratories, Inc. dated June 11, 2004. (This agreement
has been redacted pursuant to a confidential treatment request filed with the SEC
on the date hereof.)
10.68 - Exclusive License, Supply and Distribution Agreement Between Leiner Health
Products, LLC and Impax Laboratories, Inc. dated July 1, 2004. (This agreement
has been redacted pursuant to a confidential treatment request filed with the SEC
on the date hereof.)
10.69 - Letter Agreement dated October 8, 2003 between the Company and Teva Pharmaceuticals
Curacao N.V. (This agreement has been redacted pursuant to a confidential treatment
request filed with the SEC on the date hereof.)"
31.1 - Certification of Chief Executive Officer pursuant to Section 302 of the
Sarbanes-Oxley Act of 2002.
31.2 - Certification of Chief Financial Officer pursuant to Section 302 of the
Sarbanes-Oxley Act of 2002.
32.1 - Certifications pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
33
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
IMPAX LABORATORIES, INC.
By: /s/ BARRY R. EDWARDS November 15, 2004
---------------------------------------------- -----------------------------
Chief Executive Officer
(Principal Executive Officer)
By: /s/ CORNEL C. SPIEGLER November 15, 2004
---------------------------------------------- -----------------------------
Chief Financial Officer
(Principal Financial and Accounting Officer)
34